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ABSTRACT 
Yersinia pestis, the causative agent of plague, specializes in causing dense bacteremia 
following intradermal deposition of a small number of bacteria by the bite of an infected 
flea. This robust invasiveness requires the ability to evade containment by the innate 
immune system. Of the various mechanisms employed by Y. pestis to subvert the innate 
immune response and to proliferate rapidly in mammalian tissue, only a few are well-
characterized. Here, I present two complementary genetic analyses of Y. pestis 
adaptations to the mammalian environment. In the first, genome-wide fitness profiling for 
Y. pestis by Tn-seq demonstrates that the bacterium has adapted to overcome limitation of 
diverse nutrients during mammalian infection. In the second, a series of combinatorial 
targeted mutations disentangles apparent functional redundancy among the effectors of 
the Y. pestis type III secretion system, and we report that YpkA, YopT, and YopJ 
contribute to virulence in mice. We have also begun to investigate a novel relationship 
between Y. pestis and mammalian platelets, a highly abundant cell type in plasma. I 
present evidence that Y. pestis has evolved specific mechanisms to interfere with platelet 
activation, likely in order to evade immune responses and promote maintenance of 
bacteremia by undermining platelet thrombotic and innate immune functions. The 
principles guiding this work – systematic genetic analysis of complex systems, coupled 
with rational modification of in vitro assays to more closely mimic the in vivo 
environment – are a generalizable approach for increasing the efficiency of discovering 
new virulence determinants in bacterial pathogens. 
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CHAPTER I : Introduction 
Of the Gram-negative bacteria in the genus Yersinia, three species are human 
pathogens. Yersinia enterocolitica and Yersinia pseudotuberculosis cause typically self-
limiting gastrointestinal illness, and are transmitted by the fecal-oral route. The third 
species, Yersinia pestis, diverged from Y. pseudotuberculosis quite recently: most reports 
date the divergence of these species to between 1,500 and 20,000 years ago (1-3), though 
a recent analysis gave an earlier estimate (4). Since its divergence, Y. pestis underwent 
several genetic changes that resulted in radical deviation from the ancestral fecal/oral 
transmission cycle and pathogenesis. Yersinia pestis causes plague in mammals, and 
primarily exists as an endemic zoonosis in rodent populations, where it is transmitted by 
the bites of infected fleas (5). Human plague infections are relatively rare, with only few 
hundred to a few thousand cases per year reported worldwide (6, 7). However, Y. pestis is 
responsible for several devastating historical pandemics, including the infamous 
European Black Death pandemic of the Middle Ages (8-10). 
Infection of susceptible mammals from a flea bite typically causes the bubonic 
form of disease, characterized by invasion of the bacterium from the dermis, massive 
bacterial proliferation in lymphoid tissue, and a sustained systemic infection 
accompanied by dense bacteremia (5). More rarely, direct access of Y. pestis to the 
bloodstream – through wound exposure to the blood of an infected animal, or through a 
flea bite that accesses a blood vessel (11) – causes septicemic plague, in which Y. pestis 
establishes bacteremia without first trafficking through the lymphatic system. Secondary 
pneumonic plague, resulting from colonization of the lungs, can sometimes be 
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transmitted directly between mammals via droplet inhalation (5). The primary pneumonic 
disease this causes is rare and extraordinarily deadly, with mortality in humans 
approaching 100% if antimicrobial therapy is not rapidly initiated (12). The much more 
common human cases of bubonic and septicemic plague are fatal in approximately 60% 
of untreated cases, though these infections are now readily treatable with antibiotics 
(retrospective data from (13)). 
As a flea-borne pathogen, Y. pestis has evolved a remarkable invasiveness and 
virulence in mammals that is unique among pathogenic Yersiniae. Following the 
intradermal deposition of a small number of bacteria by the bite of an infected flea, Y. 
pestis must disseminate and maintain dense bacteremia to ensure colonization of naïve 
fleas taking a blood-meal. The 50% infectious dose for the common Y. pestis flea vector 
Xenopsylla cheopis is approximately 5x103 colony forming units (CFU), which must be 
delivered in a ~0.1μL blood-meal (14). Very few (>10) Y. pestis bacteria are required to 
cause disease in mammals; and yet, to support flea colonization and vector-borne 
transmission, titers in the blood of late-stage infected mammals routinely exceed 107 
CFU/mL (5). 
The dissemination and massive proliferation of Y. pestis during mammalian 
infection represents a catastrophic failure of the innate immune system. Y. pestis employs 
a constellation of active bacterial processes to undermine various aspects of innate 
immunity. Some of these, such as the type III secretion system, are shared in other 
Yersiniae; others, such as the plasminogen activator Pla, are unique to Y. pestis (see 
below). Each of these adaptations is indispensable for virulence. Numerous reports have 
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demonstrated that interfering with any one of these immune subversion mechanisms 
results in substantial attenuation of Y. pestis. 
The existence of separate systems in Y. pestis to disable various arms of the innate 
immune response, and the marked attenuation that accompanies the disruption of any one 
of these systems, clearly illustrates the importance of innate immune suppression in Y. 
pestis pathogenesis. It also makes Y. pestis pathogenesis an ideal model system in which 
to study interactions between pathogens and the mammalian innate immune system. By 
interfering with one bacterial immune subversion pathway and leaving the others intact, 
the effects of a single branch of innate immunity can be studied in isolation. For example, 
at 37°C, Y. pestis alters the structure of its lipopolysaccharide (LPS) to contain tetra-
acylated rather than hexa-acylated lipid A. The tetra-acylated form of Y. pestis LPS does 
not stimulate signaling through mammalian Toll-like receptor 4 (TLR4), and therefore 
fails to induce TLR4 activation of NF-κB signaling. An altered strain of Y. pestis that 
produces hexa-acylated (TLR4-stimulating) LPS at 37°C is highly attenuated in a TLR4-
dependent manner (15), despite the presence of other functional immune-suppressing 
virulence systems. Subsequent comparisons of Y. pestis strains expressing stimulatory 
and non-stimulatory LPS have been used to define the particular contribution of TLR4 
signaling to various immune responses in the context of an active infection (16, 17). This 
pattern – the discovery of a bacterial adaptation to the host environment, followed by the 
use of this information to develop tools that enhance basic immunological research – is 
one of the most important contributions of the Y. pestis pathogenesis field. 
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As a natural rodent pathogen and a genetically manipulable organism, Y. pestis 
infection of laboratory mice is a highly tractable model system with direct relevance to 
natural disease. The strong evolutionary pressures that Y. pestis is subjected to as a flea-
borne pathogen make it especially well-suited for addressing the following questions: 
(1) What barriers do mammalian hosts employ to prevent the proliferation and 
dissemination of Gram-negative pathogens? 
(2) What are the bacterial mechanisms that allow invasive bacterial pathogens in 
general, and Y. pestis in particular, to overcome these barriers? 
(3) How do vector-borne bacterial pathogens such as Y. pestis prevent clearance 
from the vascular compartment in order to maintain the bacteremia needed for 
transmission? 
Identifying the mechanisms by which Y. pestis virulence determinants promote 
mammalian infection is a first step in answering all of these questions. Historically, the Y. 
pestis pathogenesis field has focused particularly on two of the most important virulence 
factors of Y. pestis: the type III secretion system and the bacterial plasminogen activator 
Pla. We present a brief overview of each of these systems below. 
Type III secretion in Yersinia 
 The double-membrane structure of the Gram-negative cell envelope complicates 
the regulated secretion of bacterial products into the extracellular environment. Gram-
negative bacteria have evolved at least five distinct secretion systems that span both the 
inner and outer membrane (type I, II, III, IV, and VI secretion systems), with an 
additional mechanism to transport substrates across the outer membrane from the 
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periplasm (type V secretion) (see (18) for a recent review). Of these, type III, IV, and VI 
secretion systems have each been shown to contribute to virulence in Gram-negative 
pathogens. The pathogenic Yersiniae are particularly dependent upon the action of their 
endogenous type III secretion system (T3SS) for virulence. This T3SS is one of the most 
important factors governing the immune evasion and resulting pathogenicity of Y. pestis. 
Since the original discovery of the type III secretion system in Y. pestis and Y. 
pseudotuberculosis (19-21), type III secretion systems have been found to contribute to 
virulence not only in the Yersiniae but also in diverse Gram-negative pathogens, 
including pathogenic species of Salmonella, Pseudomonas, Vibrio, Burkholderia, and in 
enteropathogenic Escherichia coli strains (22-28). In all of these pathogens, as in Y. 
pestis, the type III secretion system(s) export certain bacterial proteins from the 
intracellular environment. Rather than simply releasing these proteins into the 
extracellular milieu, the T3SS injects these bacterial proteins, called effectors, into the 
cytoplasm of target eukaryotic cells. Once inside the target cell, effector proteins 
typically interfere with host cell pathways to create an environment more favorable to 
bacterial survival, proliferation, or dissemination. 
 The machinery of the type III secretion system (T3SS) is broadly conserved 
across clades, but is perhaps best understood in Yersinia. A needle-like structure 
assembled from multiple copies of a single subunit protein – YscF in Yersinia (29) – 
extends outwards from the bacterial envelope, where it is anchored in a basal apparatus 
that derives evolutionarily from the flagellar basal body (30-32). A separate protein 
(LcrV in Yersinia (33)) is present at the distal tip of the needle. 
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 Translocation of effector proteins into the cytoplasm of target cells requires 
contact between the host cell membrane and LcrV. In particular, LcrV interacts with two 
translocon proteins that self-assemble to form a small pore in the membrane of the target 
cell. The interaction between LcrV and the translocon proteins (in Yersinia, YopB and 
YopD) is thought to create a continuous conduit between the cytosol of the bacterium and 
the target cell via the hollow YscF needle, and this syringe-like “injectisome” apparatus 
delivers effector proteins to target cells by passing them through this channel (34). The 
diameter of the lumen of this channel is narrow: approximately 2.5 nm in the needle (35) 
and 2-3 nm in the translocon pore (36). If effector proteins pass through this lumen, then, 
they must do so unfolded. The AAA+ family ATPase powering the T3SS has been 
proposed to mediate this unfolding and loading into the needle structure (37, 38). In spite 
of recent reports that are not entirely consistent with this model (39, 40), the 
“injectisome” hypothesis remains the predominant working model for the mechanism of 
type III secretion. 
 Effector proteins of various T3SSs vary widely between pathogens. Very 
generally, T3SS effector proteins coopt host cell signaling in some way that benefits 
bacterial survival or increases virulence. The particular pathway(s) that a given effector 
targets, and the enzymatic activity (if any) that it employs, can sometimes be predicted by 
homology. However, different pathogens contain different sets of effector proteins, and 
these effectors may modulate the activities of one another by targeting related or 
interacting pathways in the same host cell. Predicting the net effect that any particular 
effector has when functioning in combination with other T3SS effectors within the 
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complex milieu of a host cell is a much more difficult problem than the prediction of 
biochemical activity, and is best addressed experimentally. 
 Some species secrete an enormous number of effector proteins through a variety 
of systems. Legionella pneumophila, for example, secretes several hundred effector 
proteins from its type IV secretion system (41). Even the more modest number of T3SS 
effectors expressed by Salmonella enterica species – approximately 30 (42, 43) – 
presents a substantial logistical hurdle to any systematic analysis focused on 
comprehensively defining individual effector functions and the outcome of interactions 
between effectors. By contrast, the pathogenic Yersiniae have only been shown to secrete 
seven effector proteins (or six, in some Y. pseudotuberculosis strains) via the T3SS. This 
unusually limited repertoire of secreted effectors makes Yersinia a particularly attractive 
system in which to study the effects of type III secretion, as a holistic model of its various 
effectors working in concert seems (at least in principle) to be within reach. 
Individual characterization of the Yersinia effectors has been fairly successful. 
Each has, at a minimum, been assigned an enzymatic activity or a primary physiological 
effect in intoxicated cells, and many have been studied in vivo as well. A comprehensive 
introduction to the seven effectors of Yersinia can be found in Chapter 3 (see page 59). 
The effects of the Yersinia T3SS as a whole are well-characterized. As a group, 
the seven T3SS effectors inhibit antimicrobial and pro-inflammatory pathways in several 
innate immune cell types. The Yersinia T3SS inhibits phagocytosis, production of 
reactive oxygen species (ROS), caspase-1 activation, and NFκB signaling, among other 
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activities (44-50). Consistent with its proposed role in undermining immune responses, 
the Y. pestis T3SS intoxicates macrophages, neutrophils, and dendritic cells in vivo (51). 
 The mechanisms that target the T3SS to particular host cell types are not well 
understood. In Y. pseudotuberculosis and Y. enterocolitica, the bacterial adhesins Inv, 
YadA, and Ail enhance type III secretion, presumably by increasing adherence to target 
cells (52-54). Both the inv and yadA genes carry inactivating mutations in Y. pestis, but 
the PsaA adhesin has been proposed to fill a similar role in promoting T3SS injection for 
this species (55). Preferential binding of these invasins to differentially expressed host 
cell receptors could influence the cell types targeted by the T3SS. In practice, however, 
many of these adhesin receptors are broadly expressed, and the Y. pestis T3SS intoxicates 
a wide variety of host cell types in vitro (34). Strong evidence exists that the Y. pestis 
T3SS targets innate immune cells during infection (51), and that CCR5 expression 
enhances delivery of T3SS effectors (56), but this does not preclude the possibility that 
T3SS intoxication of other host cell types is also important for Y. pestis pathogenesis. The 
full range of cell types targeted by the T3SS during infection is not known. 
 The T3SS is essential for virulence in mammals, but the importance of some of 
the individual effector proteins is unclear. The virulence requirement for each effector 
protein seems to be variable: some are essential in vivo, some contribute more modestly 
to bacterial virulence, and others seem to be entirely dispensable. (See page 62 of Chapter 
3 for further details.) It is not known whether the latter class of effectors are truly 
unimportant for bacterial fitness during mammalian infection, or whether some functional 
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redundancy within the T3SS prevents single deletions of these effectors from suffering 
attenuating phenotypes. 
During infection, the T3SS of Y. pestis suppresses immune responses and 
promotes bacterial survival in vivo. These activities are essential for the virulence and 
invasiveness that underlies the pathogenic lifestyle of Y. pestis. The activity of the T3SS, 
however, is not sufficient to completely suppress immune responses; for example, the 
presence of the T3SS cannot compensate for the production of TLR4-stimulating LPS in 
genetically altered Y. pestis strains (15). Nor does the Y. pestis T3SS explain the radically 
different pathogenesis of this organism from Y. pseudotuberculosis, as the T3SS is 
closely conserved between these species. Next, we consider genetic elements of Y. pestis 
which are absent from Y. pseudotuberculosis, and which contribute uniquely to the 
increased invasiveness and virulence of the plague bacterium.  
The Pla protease and plasminogen activation 
Many of the changes that occurred during divergence of Y. pestis from Y. 
pseudotuberculosis were gene loss events. More than 10% of Y. pseudotuberculosis 
genes are inactive in the Y. pestis genome (57). However, Y. pestis also acquired new 
genetic material that is absent from the other pathogenic Yersiniae. This includes two 
plasmids, each of which contributes to the vector-borne infection strategy of Y. pestis. 
The first of these plasmids, the ~9.5 kilobase plasmid pPCP1, is discussed here; the 
second, pMT1, is discussed below. 
The pPCP1 plasmid is essential for the virulence of Y. pestis in mammals (58), but 
is not present in Y. pseudotuberculosis or Y. enterocolitica (59). This small plasmid 
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encodes the pesticin bacteriocin, the corresponding pesticin immunity protein, a single 
copy of IS100, and the Pla protease, which has plasminogen activating activity (60, 61). 
Pla is an outer-membrane β-barrel protease of the omptin family, closely related 
to OmpT of E. coli and PgtE of S. typhimurium (62, 63). This protease is the crucial 
virulence factor encoded by pPCP1. The LD50 of Y. pestis mutants lacking Pla increases 
approximately one million-fold for the subcutaneous route of infection (64). Pla is also 
essential to cause bubonic disease from flea-bite infection (11). The attenuation of Pla-
deficient Y. pestis mutants does not result from a general growth or survival defect of the 
bacterium in vivo: bacterial growth at the injection site does not require Pla (64, 65), and 
infection through more central routes (intravenous or intraperitoneal) can bypass the 
requirement for this protease ((58), among others). Instead, Pla mediates virulence by 
enabling Y. pestis to disseminate to the vascular compartment from a peripheral infection 
site (e.g. the dermis). This invasiveness is crucial for maintaining the flea-borne 
transmission cycle of Y. pestis, as discussed above. 
The mechanism by which Pla promotes dissemination of Y. pestis to the vascular 
compartment seems to involve the dysregulation of mammalian hemostasis. Pla was 
initially identified as an activator of mammalian plasminogen, an abundant zymogen in 
plasma (60). Plasmin, the enzymatically active product of plasminogen cleavage, acts as 
a serine protease to degrade a variety of host proteins [reviewed in (66)]. Perhaps the 
most important target of plasmin in hemostasis is fibrin, a protein that crosslinks with 
itself to form an important structural component of clots (67). The inability of 
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plasminogen-deficient mice to degrade fibrin results in the accumulation of thrombi in 
the vasculature, and as a result these mice suffer poor health (68, 69). 
While fibrinolysis by plasmin is important for mammalian health, it must be kept 
in check to permit productive clot formation and to limit bleeding. To ensure that 
plasminogen is activated only when appropriate, mammalian plasminogen activators and 
inhibitors tightly regulate plasmin activity (Figure 1.1). During Y. pestis infection, 
however, the Pla protease activates plasminogen by cleaving it at the same site 
recognized by host plasminogen activators (64) while simultaneously degrading the 
mammalian plasmin inhibitors α2-antiplasmin and α2-macroglobin (70). Together, these 
activities cause uncontrolled plasmin activation resulting in increased degradation of a 
variety of substrates, including fibrin (see Figure 1.1). 
In addition to activating plasminogen, Pla has been reported to bind various 
proteins in the extracellular matrix (ECM) and basement membrane (BM) (71-73) and to 
mediate bacterial attachment to and invasion of cultured epithelial or endothelial cells 
(74-76). There is clear evidence that Pla has at least some plasminogen-independent role 
in both bubonic and pneumonic plague. However, the functional contribution of these 
particular plasminogen-independent activities of Pla to virulence from the bubonic route 
of infection is not clear. While Pla-mediated plasminogen activation is likely not the only 
way in which Pla contributes to Y. pestis pathogenesis, its importance in vivo is well 
established. Despite their otherwise poor health, plasminogen-deficient mice are less 
susceptible to Y. pestis infection than their wild-type counterparts, supporting the notion 
that bacterial activation of plasminogen contributes to virulence (77, 78). 
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Figure 1.1. Effects of Pla on the mammalian plasminogen activation system. The mammalian 
proteins tissue-type plasminogen activator (tPA) and urokinase (uPA) convert the plasminogen 
zymogen to active plasmin by proteolytic cleavage in vivo. Down-regulation of this process 
requires the plasminogen activator inhibitors (PAIs), which inhibit tPA and uPA, and the plasmin 
inhibitors α2-antiplasmin and α2-macroglobin. Activated plasmin directly degrades fibrin, 
laminin, and fibronectin; it also activates collagenases that degrade collagens. The bacterial Pla 
protease, shown in yellow, activates plasminogen by proteolytic cleavage and degrades the 
mammalian plasmin inhibitors. Figure adapted from (66). 
 
The mechanism by which Pla-activated plasmin enhances Y. pestis virulence is 
not fully understood. Presumably, plasmin promotes bacterial dissemination by degrading 
one or more substrates that would otherwise interfere with Y. pestis invasiveness in some 
way. However, plasmin has a plurality of substrates (66), and many of these have been 
postulated to be the crucial target for Pla-activated plasmin during infection. One 
prevalent hypothesis is that Pla-activated plasmin degrades components of the ECM or 
BM, enhancing escape of Y. pestis from peripheral tissue by increasing the permeability 
of these barriers (71-73). This hypothesis has not been tested in vivo. 
There is substantial in vivo evidence that fibrin is a crucial target for Pla-activated 
plasmin during Y. pestis infection. When infected with Y. pestis, mice deficient in both 
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plasminogen and fibrinogen lose the survival benefit conferred by plasminogen 
deficiency alone (77). This strongly suggests that fibrin contributes to mammalian control 
of Y. pestis infection, but that Pla promotes degradation of fibrin by plasmin in order to 
circumvent this control. In support of this hypothesis, fibrin accumulates around foci of 
Pla-deficient, but not wild-type, Y. pestis after intravenous (78) or pulmonary (79) 
infection. This local fibrin deposition during Y. pestis infection correlates with bacterial 
attenuation, increased effectiveness of innate immune responses, and mammalian 
survival. 
The role of fibrin in supporting innate immune responses against Y. pestis is an 
modern functional example of the ancient evolutionary link between the coagulation 
system and innate immunity (80, 81). However, the mechanism that links fibrin 
deposition and increased efficacy of the innate immune response to Y. pestis is not 
known. Defining this relationship is the next key step in understanding how Pla 
contributes to Y. pestis pathogenesis, and has the potential to uncover conserved 
pathways of functionally important crosstalk between the hemostatic and immune 
systems. 
Crosslinking between fibrin(ogen) monomers during coagulation results in the 
formation of gel-like fibrin aggregates. In the context of infection, cross-linked fibrin 
networks may simply provide a mechanical barrier to bacterial spread. This hypothesis 
has not yet been tested for Y. pestis. However, fibrin interacts with a variety of cell types 
that may also contribute to containment of Y. pestis strains in the absence of Pla-mediated 
plasminogen activation. For example, the fibrin gamma chain binds to the Mac-1 integrin 
 14 
expressed on leukocytes (82), and this engagement can slow cell migration (83, 84) and 
activate various antimicrobial responses [reviewed in (85)]. Indeed, fibrin deposition near 
Pla-deficient Y. pestis in vivo appears to be required for recruitment of innate immune 
cells to these lesions in liver tissue (78), though the involvement of the Mac-1 integrin in 
particular has not yet been determined for this interaction. 
In hemostasis, platelets are the primary physiological binding partner of 
fibrinogen. These anucleate cell fragments, derived from megakaryocytes in the bone 
marrow, are a crucial initiator of thrombosis and a major component of thrombi (86). 
Interestingly, platelets also carry out immune cell-like functions. Upon activation and 
degranulation, platelets release chemokines and antimicrobial peptides (87, 88). Platelets 
can also generate reactive oxygen species (ROS) directly, albeit at lower levels than 
neutrophils (89); they express all of the Toll-like receptors (TLRs), at least some of 
which are functional (90-92); and they interact with neutrophils to promote neutrophil 
antimicrobial functions and the formation of neutrophil extracellular traps (NETs) (90, 
93). Despite their status as a classical component of the hemostatic system and their 
increasingly recognized role in response to infection, immune responses of platelets have 
never been investigated as a potential target for Pla-mediated immune subversion. 
Other virulence factors of Y. pestis 
 The plasmid-borne T3SS and plasminogen activator are perhaps the most widely 
studied virulence factors of Y. pestis, though they are by no means the only loci in the 
genome that contribute to Y. pestis pathogenesis. Several other factors with strong effects 
on the virulence or transmission of Y. pestis are discussed here. 
 15 
pMT1. The ~100 kilobase plasmid pMT1, absent from Y. pseudotuberculosis and Y. 
enterocolitica, is not directly required for virulence in rodents. Rather, pMT1 encodes 
several functions that enable flea colonization and transmission. Two loci on the pMT1 
plasmid are particularly important for this route of transmission: the ymt gene and the 
locus encoding the capsule-like antigen caf1 (F1 pili). 
Ymt was initially identified as a murine toxin, and indeed, recombinant Ymt 
protein is highly toxic in mice (94). Ymt was therefore initially proposed to increase 
pathogenicity of Y. pestis during rodent infections (95). However, later work 
demonstrated that ymt does not contribute to Y. pestis virulence during mammalian 
infection (96). Instead, the ymt gene encodes a phospholipase D that promotes Y. pestis 
survival in the flea gut, presumably by interfering with some as-yet unidentified 
arthropod immune response (97). Acquisition of this gene was presumably a crucial step 
in the evolution of Y. pestis as a flea-borne disease. 
As a capsular protein, caf1 has sometimes been described as anti-opsonic, and is 
reported to limit phagocytosis by macrophages (98). However, the effect of caf1 on 
virulence in mice through the subcutaneous route of infection varies depending on the 
genetic background of the mice (99). It appears that caf1 is particularly important for Y. 
pestis to successfully establish mammalian infection via the flea-bite route (100). When 
the Caf1 protein is not expressed, Y. pestis form aggregates both in vitro (unpublished 
observations) and in vivo (100), which may hinder dissemination of the bacterium from 
the dermis. Expression of Caf1 likely changes the biophysical properties of the Y. pestis 
surface in some way that helps to prevent aggregation of bacteria early during infection. 
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Pigmentation locus. The pigmentation locus pgm is a ~102 kilobase chromosomal region, 
so named because it encodes hms genes that bind hemin or Congo Red dye on solid 
growth media, which gives bacterial colonies a colored appearance. The pgm locus is 
flanked by identical insertion elements that spontaneously recombine with one another at 
low frequency to generate Δpgm strains (101). Deletion of the pgm locus causes robust 
attenuation of Y. pestis (102). 
 The primary virulence defect of Δpgm strains is in iron acquisition, due to the loss 
of the biosynthetic and transport machinery for the yersiniabactin siderophore encoded on 
this region of the chromosome (103, 104). Iron scavenging by siderophores is a 
conserved virulence strategy shared by many pathogens, as iron sequestration is a key 
acute-phase response of the innate immune system. 
Metabolism and nutrient acquisition. In addition to the iron acquisition system encoded 
on the pgm locus, several other pathways involved in nutrient acquisition are known to 
contribute to Y. pestis fitness during mammalian infection. Purine biosynthesis pathways 
have long been known to be essential for growth and virulence of Y. pestis in vivo (105), 
although these same pathways are not always required for growth in vitro on rich media. 
The aromatic amino acid importer AroA has also been shown to contribute to fitness of Y. 
pestis during infection (106). These results indicate that the bacterium is faced with 
multifaceted nutrient restriction in the in vivo environment, though the full extent of this 
restriction and bacterial systems to circumvent it is not known. 
Systematic approaches to probe host/pathogen interactions in Y. pestis 
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 The T3SS, the Pla plasminogen activator, and the pgm pigmentation locus were 
identified as virulence factors relatively early in the study of Y. pestis pathogenesis, 
because spontaneous mutants lacking each of these factors could be readily isolated 
(plasmid segregants or Δpgm recombinants), and each had some striking in vitro 
phenotype. Mutants lacking the pgm locus were notable for the failure of their colonies to 
bind Congo Red or hemin. Loss of the pPCP1 plasmid resulted in loss of in vitro 
fibrinolysis activity and sensitization to the Y. pestis bactericin pesticin (107). Loss of the 
pCD1 plasmid or inactivating mutations of the T3SS reversed the rather unusual calcium 
dependence of Y. pestis for growth at 37°C, and as a result these mutations were simple 
to select for in vitro (108). The identification of these virulence factors shaped the focus 
of Y. pestis pathogenesis research for decades to come, and indeed these virulence factors 
are still some of the most important known determinants of Y. pestis pathogenesis. 
However, the non-systematic way in which these initial virulence factors were identified 
leaves open the possibility that important determinants of Y. pestis virulence are still to be 
discovered. 
 Candidate gene approaches have recently identified several other factors 
important for Y. pestis pathogenesis (for example (109-112)), some of which are under 
development as potential mechanisms of attenuation for live vaccine development. 
However, candidate-based approaches have a high failure rate and are relatively low-
throughput. Complementary high-throughput approaches to identify novel virulence 
factors of Y. pestis are beginning to close this gap through transcriptomics (113-117) and 
functional assays of defined mutant libraries (118, 119). However, prior to the 
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publication of this work, no functional assay for bacterial fitness at the genome level had 
been reported for Y. pestis growing in deep tissue. 
Thesis objectives 
 In this thesis, we employ bacterial genetic approaches to determine how Y. pestis 
manipulates the host environment in order to establish and maintain the dense bacteremia 
that is a prerequisite for the successful flea-borne transmission of bubonic plague. In 
particular, we pursue three goals: 
1. The acquisition of functional phenotypic information to determine the importance 
of various Y. pestis genes. This includes the use of Tn-seq, a genome-wide fitness 
profiling technology, to comprehensively search for Y. pestis genes required for 
bacterial fitness during infection. We also emphasize the use of in vivo phenotypic 
testing and the development of physiologically relevant experimental models, as 
these allow us to more confidently extrapolate measured phenotypes to the 
context of natural Y. pestis infection. 
2. The dissection of apparent functional redundancies using combinatorial genetic 
manipulations, informed by biological hypotheses. This approach, complementary 
to the high-throughput genomics approach on Tn-seq, allows us to build a more 
comprehensive and accurate model of complex systems with multiple interacting 
components, such as the T3SS of Y. pestis. 
3. The development of in vitro assays that more closely recapitulate the in vivo 
environment. To increase the quality of information gathered from in vitro and ex 
vivo studies of Y. pestis gene function, we modify in vitro assay systems wherever 
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possible to include more physiologically relevant conditions. The resulting 
experimental systems allow us to use in vitro work to identify a greater number of 
bacterial functions that contribute to fitness in vivo. 
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CHAPTER II : Genome-wide mutant fitness profiling identifies nutritional 
requirements for optimal growth of Yersinia pestis in deep tissue 
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Introduction 
Serendipitous quirks of Yersinia biology catalyzed much of the research into the 
molecular basis of Y. pestis pathogenesis in the last three decades. For example, the 
finding that the addition of skim milk to the growth medium enhanced retention of 
virulence of Y. pestis cultured at 37°C (108) ultimately led to the discovery of type III 
secretion (21). The identification of the yersiniabactin siderophore system required for 
bacterial iron acquisition during infection (103, 120) was similarly prefaced by the 
observation that the ability of Y. pestis to form pigmented colonies on media containing 
hemin was somehow linked to virulence (102, 121). A large fraction of current research 
on Yersinia virulence centers exclusively on the handful of virulence determinants 
discovered by these early efforts. To date, these studies have largely eclipsed more 
systematic attempts to define virulence determinants and other important factors 
contributing to severity of disease. 
 The limitations of previous iterations of whole-genome techniques are partly 
responsible for this focus. Prior genomic level studies of Y. pestis relied on acquisition of 
gene expression data under various in vitro and in vivo conditions (113-117). These 
results provide a deeper understanding of physiological adaptations employed by the 
bacterium in different environments; however, gene expression data has not proved a 
reliable predictor of virulence determinants (122-124). Attempts to circumvent this 
problem by directly measuring the functional contribution of Y. pestis genes to bacterial 
growth in vivo have been more successful, but these rely on measuring the fitness of a 
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defined panel of mutants rather than implementing a truly unbiased genome-scale 
technique (118).  
Recently, the combination of transposon mutagenesis and high-throughput 
sequencing has provided a more direct approach to functional genomics. This method has 
been assigned several names, including HITS (125), TraDIS (126), INSeq (127), and Tn-
seq (128). Tn-seq employs deep sequencing to map and count transposon/genome 
junctions from a dense library of random transposon insertion mutants grown en masse in 
each condition of interest. The number of transposon insertions detected in a given gene 
reflects the prevalence of the corresponding mutants in the library following selection 
(129). This information can be used to estimate relative fitness for mutants in different 
growth environments. 
Tn-seq is an increasingly popular tool in studies of bacterial pathogens (124-140), 
although to date only five pathogens have been examined using animal infection as a 
selection regime (Streptococcus pneumoniae (132, 135), Haemophilus influenzae (125), 
Yersinia pseudotuberculosis (134), uropathogenic Escherichia coli (139), and 
Mycobacterium tuberculosis (140)). Here, we use Tn-seq to measure the fitness of nearly 
200,000 unique Y. pestis insertion mutants during growth in vitro in rich culture medium 
and in mice following intravenous inoculation. We identified several genes contributing 
to bacterial fitness during infection that had not previously been implicated in virulence, 
including more than thirty genes with roles in nutrient import and metabolism. The 
majority of known virulence factors required for optimal bacterial growth during 
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infection were also required in the Tn-seq dataset, underscoring the suitability of this 
method in the context of infection studies. 
Results 
Transposon mapping of the Yersinia pestis genome. We mutagenized the fully virulent 
Y. pestis strain KIM1001 with a himar1-derived transposon to construct a bank of 
approximately 1.5 million independent insertion mutants. To select against mutants 
harboring insertions in genes required for growth in vitro, the insertion library was grown 
on TB, a complex medium adapted from tryptose blood agar base that provides a broadly 
permissive growth condition for insertion mutants. 
To select against mutants harboring insertions in genes required for growth during 
mammalian infection, we performed intravenous infections of three C57BL/6 mice with 
2.3 x107 CFU of the insertion library, which resulted in a population of ~106 bacteria in 
each spleen one hour post-infection. This infection route preserves library diversity by 
circumventing bottlenecks imposed by peripheral routes of infection. Bacteria were 
recovered from spleens 40 hours post-infection by plating on TB agar. Bacterial 
populations in the spleen at the time of harvest averaged 1.63x109 CFU/spleen (ranging 
from 1.4x109 to 2.1x109).  This population expansion is in excess of 1,000-fold, large 
enough to permit detection of modest reductions in fitness even in the absence of 
bacterial killing by host defenses.  
 24 
 
Figure 2.1. Dense transposon mapping of the Y. pestis genome allows identification of 
regions under selection. The number of insertions sequenced at each site is represented by bar 
height (log scale). Circular plots were generated using CGView (141). (A) Transposon insertions 
mapping to the chromosome. Large gaps correspond to blocks of essential genes, such as the 
NADH dehydrogenase subunits (inset; insertions are shown by Integrated Genome Viewer (142, 
143) on a log scale). (B) Transposon insertions mapping to the type-III secretion plasmid pCD1. 
Insertions in many genes in the first 30 kilobases of pCD1, which encode regulatory and 
structural components of the type III secretion system, are selected against in vivo (outer ring; red 
bars) but not in vitro (inner ring; blue bars). The gap of insertions at the 60 kilobase mark 
corresponds to plasmid replication genes. 
 
Following selection, we mapped the transposon insertions present in the bacterial 
populations recovered from the in vitro and in vivo expansions via selective amplification 
of transposon-genome junctions and Illumina sequencing, using methods similar to those 
previously described (see Supporting Text S1 of (144) for detailed methods.). The himar1 
transposon derivative used for mutagenesis inserts at TA dinucleotides (145, 146). 
Approximately 69% (187,780 of 271,354) of TAs in the Y. pestis KIM genome harbored 
insertions, an average density of 39 insertions per kilobase. This high density of 
 25 
insertions allowed fine-scale mapping of functional genetic units, including intergenic 
regions (Figure 2.1A). The density of mutations on pMT1, pCD1, and pPCP1, the three 
plasmids present in Yersinia pestis KIM, was similar to that on the chromosome (78% on 
pMT1, 76% on pPCP1, and 63% on pPCP1, compared to 69% on the chromosome) 
(Figure 2.1B). Although substantial large-scale heterogeneity in insertion density has 
been observed after similar transposon mutagenesis of other pathogens (130, 147), 
insertions in our library were distributed relatively evenly across the chromosome (Figure 
2.1A). 
Identifying genes required for optimal growth in vitro. To identify genes required for 
optimal growth of Y. pestis on rich medium, we analyzed the full set of Y. pestis KIM 
ORFs annotated in the NCBI database by two distinct mathematical approaches for 
measuring the effect of insertions on fitness. 
Relative fitness analysis. In the first approach, we estimated the relative fitness (W) of 
mutants harboring insertions in each chromosomal ORF, using a similar analysis to that 
described by van Opijnen and Camilli (148). In the context of evolutionary biology, 
relative fitness is defined as the ratio of the rates of population expansion for the two 
genotypes being compared. Mutants with relative fitness < 1 are defective in growth or 
survival relative to wild-type, while mutants with relative fitness > 1 are more fit than 
wild-type. To test the statistical significance of the observed changes in fitness for each 
gene, we employed a nonparametric approach based on a reference distribution created 
by resampling insertion frequencies in TA sites in nonessential ORFs (defined as those 
with relative fitness between 0.95 and 1.05) and plotted relative fitness versus 
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significance (Figure 2.2A) (method details are described in the Addendum to Chapter 2, 
page 50; complete results available in Table S1 of (144)). 
 
Figure 2.2. Selection of chromosomal Y. pestis genes during growth in vitro on rich medium. 
(A) The relative fitness of mutants in each chromosomal ORF plotted against significance 
(calculated by resampling; see addendum of this chapter, page 54). Genes harboring no 
sequenced insertions in the central 90% of the ORF (relative fitness = 0) are shown in the box at 
the left of the plot.  (B) Relative fitness (histogram) correlates well to essentiality as predicted by 
the hidden Markov model recently published by DeJesus and Ioerger (149) (red, essential; 
yellow, growth-deficient; green, nonessential). Genes harboring no sequenced insertions in the 
central 90% of the ORF (relative fitness = 0) are shown in the box at the left of the plot. (C) 
Three examples of genes with modest reductions in relative fitness that were predicted to be 
essential by the hidden Markov model. Many genes in this class contain groups of consecutive 
TA sites that do not harbor insertions (red boxes), suggesting domain architecture. For example, 
 27 
the apparently essential N-terminus of the rne gene is highly homologous to the essential E. coli 
gene of the same name (150, 151), while the evidently nonessential C-terminus is highly 
divergent from the E. coli homologue, as has been reported for several other species (152). Also 
shown is the apparently essential C-terminal DNA-binding domain of the rcsB gene, a 
transcriptional activator with multiple roles including small RNA production and cell division 
(153). Insertions are shown by Integrated Genome Viewer (142, 143) on a log scale. 
 
Hidden Markov model analysis. A drawback of the fitness approach is its insensitivity to 
ORFs containing multiple functional domains with differing contributions to fitness. To 
address this problem, we used the hidden Markov model (HMM) recently developed by 
DeJesus and Ioerger (149). This method classifies genes as essential, growth 
disadvantaged, non-essential, or growth advantaged. A complete list of classification of 
ORFs by the HMM algorithm is available in Table S2 of (144). The metabolic pathways 
most commonly represented by this list of genes, as mapped by the Kyoto Encyclopedia 
of Genes and Genomes (154), are summarized in Table S3 of (144). Relative fitness 
values were good predictors of HMM class (Figure 2.2B), indicating general agreement 
of these two methods. However, a small number of genes classified as essential or growth 
deficient by the HMM were assigned relatively high relative fitness values (above 0.75). 
Comparison of relative fitness and HMM approaches. In some cases, identification of 
high-fitness ORFs as essential is consistent with known domain structure; this algorithm 
is particularly sensitive to consecutive TA sites without insertions, and therefore correctly 
classifies ORFs containing sub-genic essential domains (Figure 2.2C). However, other 
genes in this group have insertion patterns that render their classification suspect. These 
include (1) genes with relatively short (<20) runs of insertion-free TAs, which are less 
likely to represent functional protein domains, and (2) runs of insertion-free TAs in 
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unusually AT-rich sequences, which may be more difficult to sequence due to base-
composition bias in library preparation and/or Illumina sequencing (155).  
 
Figure 2.3. Length of the longest 
insertion-free window of ORFs 
identified as “essential” by the HMM. 
The mean length of the longest insertion-
free window is greater, and the distribution 
shows greater skew toward longer window 
lengths, for HMM-called essentials with W 
< 0.672 (<1 insertion per TA).  This 
suggests that the HMM algorithm has 
excessive sensitivity to the presence of 
short windows, which are more likely to 
occur by chance and less likely to encode 
independent functional protein domains. 
Note: because there are many more genes 
in the W < 0.672 class than in the W >= 
0.672 class, histograms show density 
(number of data points in the category / 
total number of data points) rather than 
frequency (raw number of data points in 
the category with no adjustment). 
 
 
We divided the HMM-called essentials into two classes: those with strong defects 
in relative fitness (<1 insertion per TA; W < 0.672) and those with more moderate 
relative fitness (W >= 0.672). The classification scheme of the HMM algorithm relies 
heavily on the length of intragenic windows free of insertion (i.e., the number of 
consecutive TA sites that do not harbor insertions). The longest insertion-free window in 
ORFs with neutral-to-moderate relative fitness phenotypes was more likely to be short 
(figure 2.3) or to have low GC content (figure 2.4). This supports the hypothesis that, 
while some discrepancies between the HMM and fitness analyses result from HMM 
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identification to domain structure, others may reflect oversensitivity of the HMM to gaps 
caused by chance or by technical error. 
 
Figure 2.4. GC content in the 
longest insertion-free window 
of ORFs identified as 
“essential” by the HMM. In 
comparison with the W < 0.672 
group, the distribution of HMM-
called essential ORFs with 
W>=0.672 (>1 insertion per TA) 
is strikingly bimodal, with a 
much greater fraction of longest 
windows having low GC 
content (<40%).  This suggests 
that such windows are a poor 
criterion for inclusion in the 
essential class, as insertions in 
these regions may be in 
underrepresented due to artifacts 
of sample processing. Note: 
because there are many more 
genes in the W < 0.672 class 
than in the W >= 0.672 class, 
histograms show density 
(number of data points in the 
category / total number of data 
points) rather than frequency 
(raw number of data points in 
the category with no 
adjustment). 
 
In vitro growth requirements for plasmid genes. The HMM analysis also identifies some 
plasmid genes as essential, including genes required for plasmid replication. The apparent 
selection on these genes does not stem from any essential function of the plasmids, but 
instead reflects the biological impossibility of propagating insertions that prevent the 
replication of their host genetic element. The plasmid pCD1, which encodes the Y. pestis 
type three secretion system (T3SS), harbors a second class of genes that the HMM scores 
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as essential or growth-deficient. The majority of these are involved in regulating T3S 
activity (e.g. yscM, lcrGVH, lcrD), and insertions in these genes are underrepresented 
because uncontrolled expression of the T3SS at 37°C in vitro inhibits growth of Y. pestis 
(e.g., (19)). Curiously, the pattern of T3SS genes selected in vitro deviates somewhat 
from current models of T3S regulation. In particular, the regulatory gene lcrE/yopN was 
not subject to significant selection in our in vitro condition (falling into the non-essential 
HMM class), and we observed unexpectedly strong selection against yopB mutants in 
vitro. We do not conceive a simple explanation for these unexpected phenotypes, and 
suggest this regulatory scheme may require further investigation. 
Identifying genes selected during infection. Because we were particularly interested in 
identifying genes required for optimal growth and survival during infection, we 
calculated the relative fitness of insertion mutants from the in vivo Tn-seq dataset. To 
determine whether the period of growth in vivo significantly changed the abundance of 
insertion mutants in each gene, we developed a nonparametric statistic based on a 
reference distribution created by permuting insertion frequencies in the relevant ORF 
from both the in vitro and in vivo datasets (see Addendum of this chapter, page 54, for 
details) and plotted the relative fitness versus significance (Figure 2.5A). A complete 
table of these values is available in Table S1 of (144). Rare genes with substantial 
reductions in in vivo relative fitness that do not reach significance (lower left of plot, 
Figure 2.5A) have large growth defects both in vitro and in vivo. 
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Figure 2.5. Comparison of Tn-seq datasets to find chromosomal genes required during 
mammalian infection. (A) Volcano plot for identification of chromosomal genes selected in 
vivo. Each gene was compared between two in vitro datasets (filled pale blue squares) or between 
an in vitro dataset and the in vivo dataset (gray circles). Genes experiencing significant selection 
in vivo are represented by black circles. For each gene, relative fitness of insertion mutants in vivo 
is given with respect to the fitness of a wild-type strain. Significance is calculated by permuting 
the number of insertions sequenced at each TA in the gene between the two datasets (see 
Addendum to this chapter, page 54). Genes selected in vivo appear in the upper left quadrant, 
while any genes that harbor more insertions in vivo than in vitro should track to the upper right 
quadrant. Genes harboring no sequenced insertions in vivo in the central 90% of the ORF (relative 
fitness = 0) are shown in the box at the left of the plot. (B) Genes experiencing strong selection 
(psn, brnQ) harbor many fewer insertions after growth in vivo. The same effect is present but less 
pronounced in genes experiencing moderate levels of selection (ptsG). Insertions are shown by 
Integrated Genome Viewer (142, 143) on a log scale. 
 
The PCR amplification and Illumina sequencing steps required for Tn-seq 
introduce variability into the measured relative abundance of each mutant in the library. 
Differences in measured abundance between libraries, therefore, may reflect either 
biologically meaningful differences or noise introduced during sample processing. To 
address this problem, we independently prepared, sequenced, and analyzed a second 
sample of the inoculum library. The comparison of these two technical replicates allowed 
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us to directly observe the extent of artefactual variation introduced by sample processing 
(Figure 2.5A). ORFs in the in vivo dataset that met a strict p-value cutoff of 0.05 and that 
fell entirely outside the range of variability observed between inoculum library replicates 
were considered candidates for significantly selected genes  
 Fifty-three chromosomal genes met these criteria for significant selection in vivo 
(Table 2.1), many of which fell into common KEGG pathways (Table S3 of (144)). 
These pathways include purine and pyrimidine biosynthesis, metabolism of both aromatic 
and certain non-aromatic amino acids, biosynthesis of secondary metabolites, and the 
ABC transporter category. Genes selected in vivo also include hypothetical genes, genes 
of unknown function, and annotated genes with putative functions that have not 
previously been implicated in Y. pestis infection. Notable among these are y0661, a 
hypothetical gene containing a conserved domain of unknown function, and y1920, a 
homologue of the LPS modification enzyme arnD that was recently reported as selected 
in the closely-related species Yersinia pseudotuberculosis during infection (134) (Table 
2.1). 
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Branched-chain amino acid transport by BrnQ is required for Y. pestis virulence. 
The putative branched-chain amino acid importer brnQ (y0981) was among the most 
strongly selected genes in vivo, despite its apparent dispensability in vitro (Figure 2.5A-
B). A homologous importer has been reported to play a role in valine uptake during 
intracellular growth of Chlamydia trachomatis (156). To validate this observed in vivo 
fitness defect, we constructed an in frame deletion of brnQ in the virulent strain 
KIM1001. Subcutaneous infection with 103 (Figure 2.6A) or 105 CFU (Figure 2.7) of the 
KIM1001ΔbrnQ1 mutant failed to visibly sicken mice, while all mice infected with wild-
type KIM1001 died within eight days. 60% of mice succumbed to infection with 107 
CFU of this mutant (Figure 2.7), indicating a roughly one million-fold increase in mean 
lethal dose in the absence of brnQ (as the LD50 of wild-type KIM1001 is less than 50 
CFU by subcutaneous infection (64)).Complementation with the brnQ gene driven by its 
native promoter on the low copy-number plasmid pSP6 restored virulence (Figure 2.6A). 
Four days after subcutaneous infection with 1000 CFU KIM1001ΔbrnQ, no Y. pestis 
could be recovered from the homogenized spleens of mice (n=5, limit of detection < 101 
CFU/spleen). 
To determine if infection with brnQ mutants could protect against subsequent 
infection, mice surviving infection with KIM1001ΔbrnQ (dose of 103 CFU) were 
challenged 28 or 30 days after the initial infection with 103 CFU of wild-type KIM1001. 
15/16 of these mice survived the challenge with no visible symptoms (Figure 2.6A). 
                                                             
1 I have used descriptive strain names such as this one to enhance readability. For full genotypic 
information and formal strain designations, see Table S1.1 (page 118). 
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Figure 2.6. Y. pestis requires the branched-chain amino acid importer BrnQ for virulence in 
mice. (A) Left: subcutaneous infection with 1000 CFU KIM1001 (w.t.) (n = 9), KIM1001ΔbrnQ 
(ΔbrnQ) (n = 17), or the complemented strain KIM1001ΔbrnQ(pSP6) (complemented) (n = 5). 
Mice infected with KIM1001 or KIM1001ΔbrnQ(pSP6) died within the first week of infection, 
while the mutant KIM1001ΔbrnQ strain failed to sicken or kill mice. Right: previous infection 
with KIM1001ΔbrnQ protected 15 out of 16 mice from subcutaneous challenge with 1000 CFU 
KIM1001 28-30 days later. (B) Growth of the attenuated strains JG150A (w.t.), JG150AΔbrnQ 
(ΔbrnQ), and JG150AΔbrnQ(pSP6) (complemented) in the defined serum-like medium SNM 
alone (left) or supplemented with 2 mM leucine, isoleucine, and valine (right). Curves are 
representative of two independent experiments.  
 
Figure 2.7. Mutants lacking brnQ are highly attenuated at high doses. Survival curves of 
mice infected subcutaneously with 105 (left) or 107 (right) CFU of the wild-type strain KIM1001 
(w.t.) or the mutant KIM1001ΔbrnQ (ΔbrnQ).  
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brnQ mutants were not under-represented in the in vitro Tn-seq dataset. To 
investigate this phenomenon, we reconstructed the in-frame deletion of brnQ in the 
attenuated strain JG150A, allowing us to investigate growth of the mutant under BSL2 
conditions. In accordance with the in vitro Tn-seq data, JG150AΔbrnQ grew as well as 
the wild-type control in the rich medium TB, and had only a mild growth defect in 
PMH2, a defined medium commonly used for culturing Y. pestis (157) (Figure 2.8A-B 
and Table 2.2). Since brnQ is annotated as an ABC transporter that imports the branched-
chain amino acids leucine, isoleucine, and valine, we formulated a new defined medium 
for culturing Y. pestis to probe for a deficiency in branched-chain amino acid acquisition. 
Serum Nutritional Medium (SNM) contains levels of magnesium, sodium, glucose, and 
all amino acids equivalent to those found in serum (Text S1 of (144)). 
The growth rate of JG150AΔbrnQ cultured in SNM is less than one-fifth of the 
growth rate for wild-type JG150A in the same medium (relative fitness 0.171). As in 
infection studies, complementing brnQ with a wild-type copy of the gene under its native 
promoter in trans restored growth of the mutant to wild-type levels (Figure 2.6B). 
Growth could also be restored by supplementing SNM with 2 mM leucine, isoleucine, 
and valine – similar concentrations to those in PMH2 (Figure 2.6B, Table 2.2). 
Interestingly, supplementing the medium with isoleucine and valine in the absence of 
leucine did not fully restore growth (Figure 2.8C), despite the presence of the apparently 
functional alternative leucine uptake system LS in Y. pestis KIM (livKHMGF, y0422-
y0426) (158) that has been reported to be expressed in vivo (113). 
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Glucose import by PtsG provides a competitive advantage to Y. pestis during 
infection. Recent work screening a defined panel of Y. pestis mutants implicated the 
glucose importer ptsG in bacterial fitness during infection (118). Like brnQ, the Tn-seq 
dataset identified ptsG as significantly selected in vivo, but insertions in ptsG caused a 
much more modest reduction in relative fitness (0.693) (Table 2.1, Figure 2.5A-B). To 
assess the contribution of ptsG to virulence, we subcutaneously infected C57BL/6 mice 
with 1000 CFU of the in-frame deletion strain KIM1001ΔptsG. The course of disease 
with KIM1001ΔptsG did not differ significantly from that with wild-type KIM1001 
(Figure 2.9). We therefore considered the hypothesis that the decrease in growth caused 
by inactivation of ptsG is insufficient to affect the outcome of infection, but that ptsG 
confers a competitive fitness advantage to Y. pestis during growth in mammals. 
 
Figure 2.9. The glucose importer PtsG has little effect 
on Y. pestis virulence. Subcutaneous infections with 1000 
CFU KIM1001 (w.t.) (n=10) or KIM1001ΔptsG (ΔptsG) 
(n=14). 13 out of 14 mice infected with KIM1001ΔptsG 
died with similar kinetics to mice infected with KIM1001. 
 
 
 We infected BALB/C and C57BL/6 mice intravenously with 104 CFU of 
KIM1001 and KIM1001ΔptsG in a 1:1 mixture. Spleens were homogenized 2 and 42 
hours post-infection and the proportion of ptsG mutants in the spleen was determined at 
each time point. The relative frequency of KIM1001ΔptsG mutants declined significantly 
over the course of the experiment (Figure 2.10A). On average, the proportion of 
KIM1001ΔptsG mutants in the spleen decreased from 0.434 at 2 hours post-infection 
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(i.e., 43.4% mutants) to 0.039 (3.9%) at 42 hours post-infection. Assuming constant 
exponential growth rates during the infection, this change in frequency corresponds to a 
relative fitness of 0.8 for KIM1001ΔptsG relative to wild-type KIM1001, a value close to 
that determined form the Tn-seq experiments (Table 2.1). 
 
 
Figure 2.10. ptsG provides a competitive advantage in the presence of glucose. (A) 104 wild-
type KIM1001 and KIM1001ΔptsG (mixed 1:1) were injected intravenously into BALB/C or 
C57BL/6 mice. The proportion of KIM1001ΔptsG mutants in the population of Y. pestis in the 
spleen was determined 2 and 42 hours post-infection by plating on TB supplemented with 2.5 
mM CaCl2, 1% glucose, and 50 μg/ml tetrazolium red. (B) The attenuated strains JG102 and 
JG102ΔptsG were mixed 1:1 in the rich medium TB, in TB supplemented with 5 mM glucose, 
and in the defined medium SNM (n = 5 for each condition). The proportion of JG102ΔptsG in 
each culture was measured before and after 42 hours of log-phase growth. 
 
We were able to recapitulate this phenotype in vitro in the defined serum-like 
medium SNM. Five replicate cultures were inoculated with equal numbers of the 
attenuated (T3SS-deficient) strains JG102 and JG102ΔptsG. After 42 hours of continuous 
log-phase growth, the proportion of ptsG mutants in the culture had decreased from 0.5 to 
an average of 0.034 (Figure 2.10B). This reduction in frequency represents a relative 
fitness of 0.794 for the ptsG mutant relative to the control strain JG102 in the same 
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medium, very similar to the value of 0.8 observed in vivo. No growth defect was detected 
in SNM when the JG102ΔptsG mutant was complemented with a low copy-number 
plasmid carrying ptsG under control of its native promoter (Figure 2.11; see Materials 
and Methods, page 111, for information about complementation). 
Figure 2.11. Complementation of the 
JG102ΔptsG mutant restores the in vitro growth 
defect. The control strain JG102ΔxylB(pZS*13luc) 
and the complemented strain JG102ΔptsG(pMP15) 
were mixed 1:1 in the rich medium TB, TB with 5 
mM glucose, or the defined medium SNM (n=5 for 
each condition). The proportion of the 
complemented strain in each culture was determined 
by plating on plates containing xylose and neutral 
red before and after 42 hours of log-phase growth. 
The increased frequency of JG102ΔptsG(pMP15) in 
TB and TB 5 mM glucose cultures is likely caused 
by slight overexpression of the PtsG importer. 
 
Because ptsG is annotated as a glucose importer, we tested whether glucose is 
required for the competitive advantage provided by ptsG. No fitness defect was detected 
for the ptsG mutant grown in the absence of glucose (Figure 2.10B), consistent with the 
apparently neutral phenotype of ptsG insertion mutants in the in vitro Tn-seq dataset 
(Figures 2.2A, 2.5B). By contrast, the proportion of ptsG mutants in cultures containing 
glucose decreased on average from 0.592 to 0.266 (Figure 2.10B). This decrease 
corresponds to a relative fitness of 0.92 for JG102ΔptsG relative to wild-type JG102 in 
this rich culture medium, supporting the hypothesis that ptsG provides a competitive 
advantage to Y. pestis during infection by permitting or increasing glucose import. 
Intercellular complementation in vivo: genes required for siderophore-mediated 
iron acquisition. Growth in vivo strongly selected against insertions in the psn gene 
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(y2404), which encodes the outer membrane TonB-dependent yersiniabactin importer 
(159), and in ybtA (y2398), the regulator required for expression of psn and other genes 
in the yersiniabactin uptake system (160) (Table 2.1 and Figure 2.5A-B). This agrees 
with an extensive body of literature describing the requirement for yersiniabactin-
mediated iron acquisition for optimal growth in iron-limiting conditions (159, 161), 
including in vivo (102-104). 
However, the genes required for biosynthesis of the yersiniabactin siderophore 
(Ybt) were not selected in vitro or in vivo (Table 2.3). This apparent contradiction almost 
certainly results from intercellular complementation. Extracellular yersiniabactin has 
been reported to complement the growth of mutants deficient in yersiniabactin 
biosynthesis even in low-iron environments (159). Because our experiments were 
performed at a relatively high bacterial density, and the vast majority of the bacterial 
population remains functionally wild-type with respect to siderophore production, the 
concentration of extracellular yersiniabactin is likely high enough to provide iron to 
mutants deficient in Ybt synthesis.  
The native Y. pestis plasmids. All three of the native plasmids in Y. pestis KIM1001 
have been shown to have virulence functions in mice. To measure the contribution of 
plasmid genes to bacterial fitness during infection, we calculated the in vivo relative 
fitness and significance for each annotated ORF on the plasmids as described above for 
chromosomal genes. 
pCD1 and genes of the type III secretion system: The type III secretion system encoded 
on the 70 kb plasmid pCD1 is essential for virulence of Y. pestis. We observed very 
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strong reductions in relative fitness of mutants defective for many T3S genes (Table 2.3). 
For example, yscF, which encodes the major structural subunit of the needle, was 
classified as a strongly selected in vivo (relative fitness = 0, Table S4). lcrV, yopB, and 
yopD, encoding the translocon apparatus, also had large reductions in relative fitness (0, 
0.55, and 0.69). Among the secreted effectors, insertions in the genes encoding the 
GTPase-activating enzyme yopE, the tyrosine phosphatase yopH, and the regulatory 
effector yopK suffered clearly significant reductions in relative fitness (Figure 2.12; Table 
2.3). We did not detect a reduction in fitness for insertions in the genes encoding 
effectors yopM (a possible inhibitor of inflammasome activation), ypkA (a 
serine/threonine kinase), or yopT (a cysteine protease). Insertions in yopJ (an 
acetyltransferase) showed weak, but not significant, positive selection. These results are 
consistent with previous studies reporting that the some effectors are crucial, while others 
appear to contribute very modestly or not at all to virulence (162-167). 
Figure 2.12. Many genes on the type III secretion plasmid pCD1 undergo strong selection 
during infection. Each gene on pCD1 was 
compared between two in vitro datasets 
(filled pale blue squares) or between an in 
vitro dataset and the in vivo dataset (gray 
circles). Genes experiencing significant 
selection in vivo are represented by black 
circles. Genes harboring no sequenced 
insertions in vivo in the central 90% of the 
ORF (relative fitness = 0) are shown in the 
box at the left of the plot. The effector 
proteins of the type III secretion system 
undergo variable levels of selection (red, 
yopH; yellow, yopE; dark blue, yopK; orange, 
ypkA; purple, yopM; pink, yopT; green, yopJ), 
while the ATPase (tan, yscN) and structural 
components (tan, yscF) undergo strong 
selection. 
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Discussion 
We detected a substantial fraction of the genes previously implicated in the 
virulence of Y. pestis (Table 2.4). Some of the virulence genes not detected have been 
shown to be important via subcutaneous but not intravenous infection (e.g. pla, yadBC), 
while others may well have this property (ail, caf1, psa – see Table 2.4). Alternatively, 
intercellular complementation may mask the requirement for caf1 and/or psa, as both of 
these genes encode highly abundant secreted proteins. Our results are also generally in 
agreement with the recent study by Crimmins et al., which reports Tn-seq data for the 
closely related species Y. pseudotuberculosis following intravenous infection. As in our 
study, these investigators found crucial roles in vivo for purine biosynthesis (purM, purH, 
purC, purD), aromatic amino acid biosynthesis (aroA, aroE), and LPS modification 
(arnD) (134). The remaining differences in our results may reflect biological differences 
between these two organisms, which differ in requirements for growth in vitro and cause 
very different diseases, but also reflects the increased sensitivity and resolution of our 
experiments, which employed a 100-fold larger library. 
A comparison of the Tn-seq dataset to the in vivo competition data for a defined 
panel of Y. pestis mutants recently published by Pradel et al. (118) reveals several genes 
with reduced fitness in both experiments. Interestingly, however, there remains 
considerable disagreement between the candidates identified by Pradel et al. and the Tn-
seq approach described here. In particular, Pradel et al. found that ptsG mutants are 
attenuated in a subcutaneous single-infection model, whereas we found that ptsG mutants 
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remained fully virulent. It is possible that the low dose used by Pradel et al. – which they 
report as 10 CFU – may explain this discrepancy. 
Many genes experiencing significant in vivo selection during the Tn-seq 
experiment have roles in nutrient import or biosynthesis. The widespread use of rich 
media containing nutritional conditions not found in the host in both clinical and research 
settings may partly explain why these genes are often overlooked as therapeutic targets. 
As an illustration of this principle, the poor fitness of brnQ mutants in vivo cannot be 
detected on the rich medium TB, but is readily apparent in media specifically designed to 
mimic nutritional conditions in serum. As illustrated by the strong immunity induced by 
infection with our brnQ mutant, importers required for nutrition in vivo may also be 
useful for the rational design of strains to be used as live vaccines. 
Even in media recapitulating the in vivo environment, a growth defect in vitro 
does not always translate to reduced virulence. The behavior of brnQ mutants versus 
ptsG mutants makes clear the important distinction between fitness and virulence: the 
detection of reduced relative fitness by Tn-seq does not necessarily imply attenuation of 
the corresponding mutant. In vivo fitness and virulence can be distinct properties, 
especially when the fitness reduction is small. 
With a few exceptions, Tn-seq studies reported to date present the observed effect 
of mutants in a given gene either as a ratio of the raw frequencies (e.g. (131)) or the log 
base 2 of this ratio (e.g. (130)). As we have done here, van Opijnen and Camilli (148) use 
the metric of relative fitness. We suggest the adoption of this measure as a standard for 
the presentation of Tn-seq results. The ratio of raw frequencies yields extreme values that 
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can be misleading. Log base 2 of these ratios is proportional to relative fitness, but the 
constant of proportionality will differ depending on experimental details, and hence this 
metric may not be directly comparable among studies. Relative fitness suffers from 
neither of these complications, and has several additional advantages: most importantly, 
its readily-interpreted biological meaning and its congruence with the formal definitions 
for the synergy or independence of mutational effects. The latter is especially useful in 
genetic interaction studies, in which libraries constructed in specific mutant backgrounds 
are to be compared with libraries constructed in the wild-type parent. 
The wealth of available data on Yersinia pestis pathogenesis enables the critical 
evaluation of the Tn-seq method in the context of infection studies. For example, the 
intercellular complementation of the yersiniabactin siderophore system suggests that 
intercellular complementation may be a common phenomenon in Tn-seq and related 
methods. In support of this conclusion, Price et al. observed strong intercellular 
complementation of the Y. pestis T3SS in lung tissue when they applied an alternate 
technique for screening transposon mutant libraries (TraSH) (176). The pattern we 
observe in the yersiniabactin system – a cluster of genes devoted to synthesis of a 
secondary metabolite not under selection, coupled to transporter under strong selection – 
may be a signature for intercellular complementation by a highly diffusible small 
molecule. In the context of pathogenesis, lack of an observed fitness deficit in Tn-seq 
studies cannot be interpreted as definitive evidence that the gene in question would not be 
important, or even essential, if the mutant were in pure culture. 
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The requirement for a large inoculum to provide good coverage of the genome is 
perhaps the most important limitation of the Tn-seq method. One of the most important 
properties of Y. pestis is its ability to produce systemic infection following intradermal 
inoculation with a few bacteria; however, this problem cannot be practically addressed by 
Tn-seq due to bottleneck effects that reduce library diversity. As the work by Pradel et al. 
illustrates, a genomic-scale approach to identifying the genes required for infection via a 
peripheral route would only be practicable with an ordered array library orders of 
magnitude smaller than the random library used here, and even then would require a large 
number of mice to limit inoculum size and overcome mouse-to-mouse variation (118). 
Nonetheless, as we have shown here, even very large inocula (in our case more than 2 
million LD50s) can yield a wealth of data that accurately reflects the underlying biology 
established over many years for Y. pestis. The in vivo application of Tn-seq is clearly an 
approach of extraordinary power that should greatly accelerate the understanding of 
many pathogens. Development of adequate libraries may be a significant obstacle in 
many species, but effort devoted to overcoming this obstacle is very likely to be a 
worthwhile investment. 
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Addendum to Chapter 2: Methods to calculate relative fitness and statistical 
significance from Tn-seq datasets 
Excerpted from the supplemental Text S1 of (144). 
Derivation and calculation of relative fitness 
The following is a more detailed explanation of the estimation of relative fitness in Tn-
seq experiments than has appeared elsewhere. In particular, we make explicit the 
assumptions underlying the derivation of the formulae used. In the case of in vivo versus 
in vitro comparisons, we clarify the approach to correcting for the extent of in vitro 
growth required in infection experiments both before infection and after recovery of 
bacteria from animal tissues. 
Formula derivation: The relative fitness of insertion mutants within a given gene can be 
estimated with knowledge of four parameters: (1) the initial frequency of the mutants 
, (2) the final frequency of the mutants , (3) the size of the initial aggregate 
population of all mutants and (4) the size of the final aggregate population of all 
mutants . Let , the ratio of the initial frequency of insertion 
mutants in a given gene to that at time t. The population of an insertion mutant in which 
the mutation is neutral will change at the same rate as the population at large, and its 
frequency will therefore remain constant. The frequency of a mutant subject to negative 
selection will decline exponentially at a rate dependent on the difference between its 
Malthusian parameter , usually defined as the difference between growth and death 
rates, and that of the neutral mutants such that at time  the ratio will be 
Fi (0) Fi (t)
N(0)
N(t) Ri t( ) = Fi t( ) /Fi 0( )
mi
mn t
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(1)  
And therefore, 
(2) 
ln Ri t( )éë ùû = mi -mn( )t  
Relative fitness, W, is defined as the ratio of the Malthusian parameters of the genotypes 
being compared. To obtain an estimate of the relative fitness of mutants in gene i 
relative to wild-type (or neutral mutants), we first solve equation (2) for , 
obtaining 
(3)  
 is simply the ratio of the insertions counted in the gene of interest at the start and 
end of the experiment. In practice, we exclude insertions in the first and last 5% of each 
ORF, as the effects of these near-terminal insertions are often not consistent with those in 
the remainder of the ORF (130). 
To obtain an estimate of  we need the measured size of the aggregate population of 
all mutants at the beginning ( ) and end ( ) of each experiment. We assume that 
this population has a Malthusian parameter very close to  Thus, 
(4)  
And therefore, 
(5) . 
Substituting for  in (3) gives 
R t( ) = e mi-mn( )t
Wi
mi /mn
Wi = mi /mn = ln Ri t( )( ) /mntéë ùû+1.
Ri (t)
mnt,
N 0( ) N t( )
mn .
N t( ) @ N 0( )emnt
mnt @ ln N t( ) /N 0( )éë ùû
mnt
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(6)   
Equation (6) is equivalent to that used by van Opijnen and Camilli (148) after Lenski et 
al. (177). Note that the relative fitness obtained in this way represents the average value 
experienced during the period of selection. 
Parameter Estimation: The following explains how we estimated the parameters 
required to calculate relative fitness as given in equation (6). 
In vitro relative fitness: Estimating relative fitness for growth in vitro presents a problem 
in that  cannot be calculated exactly, because cannot be accurately measured. 
The process of making the library of insertion mutants requires a period of antibiotic 
selection to obtain the mutants. During this time, insertions in essential and strongly 
selected genes are lost, and mutants with moderate defects decline in frequency prior to 
harvesting of DNA for Illumina sequencing. One potential solution to this problem is to 
sequence transposon junctions from two or more samples subject to selection for different 
periods (e.g. see (148, 178)). An alternative approach, which we employ here, is based on 
the assumption that at the time of mutagenesis, the density of insertions in all genes is 
nearly equal, and that this initial density can be estimated by the density of insertions in 
neutral mutants after library expansion. We used a two-step process to identify a 
reference population of TA insertion sites subject to minimal selection. First, a 
preliminary value of  was calculated for every ORF. In this first calculation,  for 
each ORF was estimated by multiplying the number of TAs in the ORF by the average 
number of insertions sequenced per TA over the entire chromosome. ORFs with 
Wi @
ln Ri t( )éë ùû
ln N t( ) / N 0( )éë ùû
+1
Ri (t) Fi 0( )
Wi Fi (0)
 53 
preliminary  values between 0.95 and 1.05 (e.g., those not exhibiting substantial 
selection in comparison to the chromosome as a whole) were identified. The average 
number of insertions per TA in this pool of ORFs was then used to calculate a new 
estimate of  as above, and final  estimates were calculated using this value. This 
approach excludes TAs in essential or strongly selected genes from the final reference 
pool, ensuring that relative fitness is calculated with respect to functionally wild-type 
genotypes. The assumption of uniform distribution of insertions at the time of 
mutagenesis is reasonable for our high density library: based on binomial probabilities, 
the average kilobase is represented by a mean of 208 insertion mutants with a standard 
deviation of only 14.4 within a population of 106 mutants. 
 was measured for each gene by counting actual sequencing reads for each  
transposon junction in the ORF. was estimated from the number of resistant 
colonies obtained following mating. was determined from dilution and colony 
counts following in vitro expansion. 
In vivo relative fitness: Estimation of in vivo relative fitness requires correction for the 
effects of all in vitro growth, both before and after selection in vivo. In our experiments, 
periods of growth in vitro occurred during making of the library, preparation of the 
inoculum, and recovery of the bacteria from infected spleens. It is easy to show that, 
except in cases where mutants become very rare and hence subject to stochastic loss, a 
fixed amount of in vitro expansion will have the same effect on mutant frequencies 
whether or not it is interrupted by a period of in vivo growth (under the assumption that in 
Wi
Fi 0( ) Wi
Fi (t)
N(0)
N t( )
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vitro fitness remains constant). The best estimate for is therefore obtained by 
sequencing a library subject to the same degree of in vitro expansion as the library from 
the in vivo treatment. Accordingly, we estimated for each ORF by counting 
junction sequences in that ORF obtained from a population grown in vitro for the same 
number of in vitro generations experienced by the library recovered from infection 
experiments.  was measured from sequence junction reads of the library following 
recovery from spleens. was estimated by counting colonies recovered from spleens 
one hour after inoculation. was estimated from counting colonies recovered from 
spleens 40 hours post-infection. 
Nonparametric statistical methods to test for significant changes in relative fitness. 
In vitro relative fitness: We used a non-parametric resampling approach to test whether 
each gene’s estimated relative fitness from in vitro experiments differed significantly 
from those calculated for unselected ORFs (the same ORFs used to estimate in 
vitro; see above). 10,000 simulated ORFs containing the same number of TAs as the ORF 
under evaluation were created by randomly drawing insertion counts (without 
replacement) from the reference pool of TAs in unselected ORFs. The total number of 
insertions assigned to each of these simulated ORFs was calculated. p-values were then 
determined by ranking the observed number of sequenced insertions in the ORF under 
evaluation against the number of insertions in the 10,000 simulated ORFs. For example, 
Fi 0( )
Fi 0( )
Fi (t)
N(0)
N t( )
Fi 0( )
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an ORF with an insertion count matching a resampled ORF at position 500 from one end 
of the distribution would be assigned a p-value of 500/10,000 = 0.05. 
In vivo relative fitness: A similar non-parametric approach was used to test whether each 
gene’s relative fitness in vivo differed significantly from a relative fitness of 1 (indicating 
no selection). Mutant frequencies were compared between the in vitro (control) library 
and the library recovered from infected spleens, which underwent 40 hours of in vivo 
expansion in addition to the same number of in vitro generations as the control library. 
Mutants with no fitness defect in vivo maintain the same frequency observed in the in 
vitro library, while insertions that reduce fitness in vivo become less common during the 
period of in vivo growth. 
To compare mutant frequencies between the two libraries, read counts were first 
normalized based on the number of insertions sequenced in endogenous transposable 
elements, which we presume are unselected. Significance values were then calculated 
ORF by ORF. For each ORF, insertion counts for all TA sites within the central 90% of 
the sequence were pooled from the two libraries being compared, and assigned randomly 
into two groups to create simulated ORF pairs. The ratio of total insertions between the 
two simulated ORFs was then calculated. This process was repeated to produce 10,000 
simulated pairs for each ORF. (Because all data points are used in all iterations, i.e. 
samples are drawn without replacement, this method technically simulates pairs of ORFs 
by permutation rather than resampling.) p-values were determined by ranking the ratio of 
insertions actually observed for each ORF with reference to the list of ratios for 10,000 
ORF specific simulated pairs. 
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This analysis depends on detection of a significant difference in mutant 
frequencies between a population subjected solely to selection in vitro and a population 
subject to selection both in vitro and in vivo. For genes experiencing strong selection in 
vitro, the frequency of mutants (and therefore read counts) will be severely reduced in 
both populations, degrading the ability to resolve fitness differences. This effect is most 
apparent when a high proportion of intragenic TAs contain zero sequenced insertions, 
limiting the number of TAs at which read abundance can differ between the two 
conditions. As a result, some open reading frames with low relative fitness values in vivo 
fail to reach the significance threshold (points on lower left of plot, Figure 2.3A): these 
are open reading frames that experience substantial selection in vitro as well as in vivo, 
and are therefore rare in the inoculum at the start of the in vivo experiment. Because we 
were primarily interested in identifying genes specifically required in vivo, we included a 
relatively extensive period of growth in vitro to select against mutants with large in vitro 
growth defects. Nonetheless, we were able to detect significant fitness defects in vivo for 
genes with substantial reductions of in vitro fitness. Examples include tonB, pyrF, and 
aroA, all of which have in vitro relative fitness values between 0.8 and 0.9 (see Table S1 
of (144)). Minimizing the extent of in vitro growth would enhance the detection of genes 
which strongly reduce fitness in vitro, but have more extreme effects in vivo. 
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CHAPTER III : Combinatorial genetic analysis of Yersinia pestis yields 
synthetic virulence phenotypes for YopJ, YopT, and YpkA through the 
subcutaneous route of infection 
 
Preface 
This chapter is adapted from an unpublished manuscript. 
Authors: Samantha G. Palace1, Megan K. Proulx1, Rose L. Szabady1, and Jon D. 
Goguen1* 
1Department of Microbiology and Physiological Systems, University of Massachusetts 
Medical School, 55 Lake Ave. N, Worcester, Massachusetts 01655, USA. 
 
SGP and JDG conceived the project and designed experiments. SGP and RLS prepared 
the manuscript. All data was generated and analyzed by SGP, either independently or in 
collaboration with MKP, except for the following experiments contributed by co-authors: 
MKP collaborated on the construction of the Y. pestis strains presented here, developed 
the macrophage cell death assay, and generated the data shown in Figure 3.6. 
RLS consulted on experimental design and implementation for neutrophil assays shown 
in Figures 3.7, 3.8, and 3.9.  
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Introduction 
 The type III secretion system (T3SS) of Yersinia pestis was one of the first 
virulence factors identified in this organism, though the mechanism by which the T3SS 
contributes to disease was not initially understood. Early observations that virulent strains 
of Y. pestis required calcium for growth at 37 °C, and that loss of this calcium 
dependence correlated to loss of virulence (108), eventually led to the discovery of the 
type III secretion system on the plasmid pCD1. Loss of pCD1 both allows calcium-
independent growth and profoundly attenuates Y. pestis in mammalian infection models 
(179-181). 
During infection, the T3SS delivers specific bacterial proteins, called effectors, 
into the cytoplasm of host cells (21, 182). Translocation of type III-secreted effectors 
(T3SE) into target cells requires the concerted efforts of the syringe-like “injectisome” 
apparatus and the translocon proteins YopB and YopD. These components are thought to 
facilitate effector delivery by forming a continuous conduit that transports effector 
proteins directly from the intracellular compartment of the bacterial cell to the cytosol of 
target cells via a YopB/D pore in the host cell membrane (34, 182, 183), though some 
recent data has challenged this model (39, 40). Type III secretion systems have been 
discovered to be important virulence factors of many Gram-negative pathogens, 
including pathogenic species of Salmonella, Pseudomonas, Vibrio, Burkholderia, 
enteropathogenic Escherichia coli, and the three human pathogenic Yersiniae (21-28). 
The mechanism of secretion and the structural components of the injectisome are broadly 
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conserved across these species, while the effectors of various T3SSs range widely in 
number and function between bacteria. 
T3SS-deficient strains of Y. pestis are avirulent in mammals. Indeed, spontaneous 
segregants lacking pCD1 are so profoundly attenuated that the absence of this plasmid is 
one of only two attenuations that exempts strains from Tier 1 Select Agent regulations 
imposed by the Centers for Disease Control (184). Mutations that compromise the type 
III secretion mechanism by inactivating injectisome components are likewise highly 
attenuating (185, 186). The T3SS of Y. pestis targets innate immune cells in vivo (51) and 
undermines a variety of antimicrobial responses in these cells, including phagocytosis, 
immune signaling, and the production of reactive oxygen species (ROS) (reviewed in 
(187)). Intoxication of these cells by the T3SS is one of the most important mechanisms 
underlying the innate immune evasion that is so crucial for Y. pestis virulence and 
transmission (see Introduction, page 2). 
All three pathogenic Yersinia species share a conserved set of seven T3SS 
effectors. These are YopH, a tyrosine phosphatase (188); YopE, a GTPase activating 
protein (189); YopK, which regulates the secretion of the other effector proteins (190); 
YopM, an inhibitor of caspase 1 activation (48); YpkA (YopO in Yersinia enterocolitica) 
a serine/threonine kinase that binds host-cell actin as a cofactor for kinase activation 
(191); YopT, a cysteine protease that has been lost from some clades of Yersinia 
pseudotuberculosis (192); and YopJ (YopP in Y. enterocolitica) an acetyltransferase that 
has also been reported to have deubiquitinating activity (50, 193, 194). 
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Since the discovery of the biochemical activities of each of these effectors, 
significant efforts have been made to find their host cell targets and to define the 
functional outcomes of these effector/target interactions. Table 3.1, reproduced from a 
recent review by Pha and Navarro (187), summarizes the postulated host cell targets for 
each of the effectors (with the exception of YopK, which is thought to associate with the 
YopB/D translocon pore rather than any host cell protein (190, 195)). This useful 
overview emphasizes the large number of reported activities for effectors of the Yersinia 
T3SS. It should be noted, however, that many of these effector/target interactions were 
discovered in Y. pseudotuberculosis or Y. enterocolitica, and have not confirmed 
specifically for the Y. pestis effectors. The close phylogenetic relationship and high 
degree of conservation between Y. pestis and Y. pseudotuberculosis often allows 
successful extrapolation of these results to Y. pestis, but individual verification remains 
important, particularly in light of the markedly different diseases caused by these 
organisms (see Introduction, page 1). Furthermore, the majority of these interactions were 
discovered in vitro – in many cases, in macrophage infection experiments – and have not 
been shown to functionally contribute to virulence or bacterial fitness in vivo. 
Historically, macrophages have been the cell type of choice for studying the 
effects of the Yersinia T3SS on host cells. As a major professional phagocyte and a 
lynchpin of immune signaling and activation, macrophages are an important cell type in 
the pathogenesis of Yersinia, including Y. pestis. However, neutrophils are also key 
players in controlling Y. pestis infection (196-198). Like macrophages, neutrophils are 
capable of controlling bacterial infection via phagocytosis. However, neutrophils also 
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effect killing of extracellular bacteria through the release of a variety of antimicrobial 
products from granules, including antimicrobial peptides, proteases, iron-binding 
proteins, and the production of reactive oxygen species (ROS) (reviewed in (199, 200)). 
Neutrophil phagocytosis, ROS production, and IL-8 secretion have been identified as 
targets for the T3SS of Y. pestis (47, 201), but the roles of specific Yersinia effectors in 
neutrophils have been catalogued much less extensively than in macrophages. 
In vivo studies to date show that the contribution of individual effector proteins to 
virulence varies by effector. YopH and YopE are both indispensable for virulence and 
bacterial fitness during mammalian infection (144, 162, 163, 202, 203). Both of these 
effectors inhibit the production of reactive oxygen species (ROS) (204, 205) and interfere 
with phagocytosis (44, 206-208), likely by targeting RhoA, Rac1, and Rac2. Y. pestis 
strains deficient in YopK or YopM are also attenuated (164, 197), though the attenuation 
associated with YopM deletion seems to vary somewhat with the strain of Y. pestis (209). 
YopM likely enhances virulence by preventing caspase 1 signaling (48, 49), while the 
attenuation of YopK mutants may stem from dysregulated secretion of the other effector 
proteins (164). YopH, YopK, and YopM have each been shown to be required for 
virulence of Y. pestis specifically through the subcutaneous infection route (164, 197, 
202), which mimics natural transmission by flea bite. 
The effector YopJ profoundly deranges signaling through host cell death 
pathways in vitro, and as a result YopJ has been intensively studied in all three 
pathogenic Yersinia species. YopJ induces caspase-8/RIP-1 mediated apoptosis in 
macrophages, inhibits transcription of pro-inflammatory cytokines by NFκB, and may 
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also stimulate caspase-1 signaling (17, 210, 211). However, Y. pestis mutants lacking the 
yopJ gene have been shown more than once to retain full virulence in vivo (166, 167). 
Single deletions of the yopT and ypkA genes have not been reported to impact 
virulence of Y. pestis in mammalian infection models. Perhaps as a result, neither of these 
effectors have been studied extensively in the context of Y. pestis infection. YopT is a 
cysteine protease that cleaves the prenylated moiety from small GTPases of the Rho 
family, including RhoA and Rac1, to reduce their activity by releasing them from the 
cytoplasmic membrane (212). In Y. pseudotuberculosis, YopT also inhibits RhoG via this 
mechanism. This activity synergizes with YopE inhibition of RhoG to decrease 
phagocytic uptake of Yersinia (213). YopT of Y. enterocolitica has been reported to 
upregulate transcript levels for the anti-inflammatory GILZ protein in HeLa cells and in a 
monocyte cell line (214), though whether this is conserved in Y. pestis or functional 
during infection is unknown. The contribution of Y. pestis YpkA to virulence is also 
unknown. Like YopT, YpkA inhibits Rho GTPases including RhoA, Rac1, and Rac2, 
though the functional importance of  Rho inhibition by YpkA for Y. pestis pathogenesis is 
not clear (summarized in (187)). 
Although YopJ, YopT, and YpkA are individually dispensable for Y. pestis 
virulence, all three effectors are conserved across natural and experimental Y. pestis 
strains. Given the small number of T3SS effectors found in Y. pestis, especially as 
compared to other pathogens with T3SSs (see Introduction, page 7), it is likely that these 
effectors have been selectively maintained and that they play a role during some stage of 
the natural Y. pestis transmission cycle. However, these three effectors do share some 
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putative targets with one another and with the other T3SS effectors at both the protein 
and pathway level (see Table 3.1). Their functions may therefore overlap sufficiently to 
account for the observation that single deletion of any one of these effectors does not 
have a measurable effect, at least in the context of standard laboratory survival studies 
employing infection of inbred mouse strains. 
Traditional single gene knockout models are ill-suited to studying the individual 
contributions of functionally redundant components of a complex system. To determine 
the effects of the YopJ, YopT, and YpkA proteins, we chose instead to test for gain-of-
function phenotypes when effectors were added back to a strain from which all seven 
effector proteins had been deleted. Using this model, we found that the four effectors 
previously reported to contribute functionally during infection – YopH, YopE, YopK, 
and YopM – are not sufficient to mediate full virulence of Y. pestis. In fact, each of the 
seven effectors was capable of contributing to virulence through a subcutaneous model of 
infection, which mimics natural infection of plague via flea bite. Furthermore, we 
confirmed that YopJ (but not other effector proteins) can directly cause cell death of 
macrophages and prevents immune cell recruitment to the liver, while YopH and YopE 
confer resistance to neutrophil killing. The mechanisms by which YopT and YpkA 
contribute to Y. pestis infection in vivo remain unclear. 
Results 
The known Y. pestis virulence effectors YopH, YopE, YopK, and YopM are 
insufficient for full virulence in vivo. To understand the functional role of each of the Y. 
pestis T3SS effector proteins during infection, we set out to find the minimal subset of 
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effectors that were sufficient to mediate full virulence through the subcutaneous route of 
infection. One of the major challenges of dissecting the functional contributions of the 
T3SS effectors in vivo is the high degree of interconnectedness among their putative 
target molecules and pathways – for example, no fewer than four distinct effectors 
(YopH, YopE, YpkA, and YopT) are reported to interfere with phagocytic function of 
innate immune cells (see e.g. Table 3.1). For this reason, if a mutation in a single effector 
fails to yield an attenuation phenotype in vivo, it is difficult to distinguish between true 
dispensability of the effector’s function and possible functional redundancy with other 
components of the T3SS. By building strains expressing various effector combinations 
from the “bottom up” – introducing effectors one at a time into a genetic background that 
originally lacked all seven effector proteins – we are able to systematically address the 
possibility of redundancy, and to find synthetic phenotypes for T3SS effectors that had 
not previously been shown to contribute to Y. pestis virulence. 
We approached this problem by first constructing KIM1001ΔT3SE2, an unmarked 
strain that retains the T3SS injectisome but carries in-frame deletions in the open reading 
frames (ORFs) for all seven effector proteins. This strain was highly attenuated through 
the subcutaneous route of infection. When infected with 1000 CFU KIM1001ΔT3SE, 0 
of 8 mice developed visible symptoms of disease, and all mice survived infection (Table 
3.2). 
  
                                                             
2 I have used descriptive strain names such as this one to enhance readability. For full genotypic 
information and formal strain designations, see Table S1.1 (page 118). 
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in all of the remaining five effectors’ ORFs, failed to sicken or kill any mice following 
subcutaneous infection with 103 CFU (n=10) (Table 3.2). 
Single deletion studies have demonstrated that YopM and YopK are also essential 
for full virulence of Y. pestis (164, 197). However, the addition of either of these 
effectors into the KIM1001ΔT3SE::+yopHE background had little effect. Strains 
expressing only YopH, YopE, and YopM (KIM1001ΔT3SE::+yopHEM) or YopH, 
YopE, and YopK (KIM1001ΔT3SE::+yopHEK) were also attenuated (0 out of 6 mice 
killed for each group following subcutaneous infection with 103 CFU) (Table 3.2), 
though 2 out of 6 mice infected with KIM1001ΔT3SE::+yopHEK lost their fur around 
the injection site and developed local redness of the skin that persisted for at least 28 
days. 
 Interestingly, although KIM1001ΔT3SE::+yopHE, KIM1001ΔT3SE::+yopHEM, 
and KIM1001ΔT3SE::+yopHEK were equally avirulent, they differed in the extent to 
which exposure to these strains conferred protective immunity. When challenged 
subcutaneously with 103 CFU of the wild-type Y. pestis strain KIM1001 28 days after 
initial infection, mice exposed to KIM1001ΔT3SE::+yopHEM or 
KIM1001ΔT3SE::+yopHEK uniformly survived the challenge, while 3 out of 10 mice 
exposed to KIM1001ΔT3SE::+yopHE succumbed within 14 days (Figure 3.1). The full 
protection from challenge conferred by exposure to KIM1001ΔT3SE::+yopHEK and 
KIM1001ΔT3SE::+yopHEM suggests that each of these strains, while nonlethal, causes 
infection that is sufficiently persistent to trigger involvement of the adaptive immune 
system. The partial protection from KIM1001ΔT3SE::+yopHE exposure is consistent 
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with the hypothesis that this strain is more susceptible to clearance by the innate immune 
system, and therefore generates a weaker or less consistent adaptive immune response. 
Although the phenotypes of these three strains were indistinguishable with respect to 
survival upon primary infection, comparison using this alternative in vivo endpoint 
demonstrates subtle additive effects of YopM and YopK. 
Figure 3.1. Protective immunity from 
exposure to Y. pestis mutants expressing 
subsets of T3SS effectors. When 
challenged with 1000 CFU KIM1001 28 
days after initial infection, mice exposed to 
KIM1001ΔT3SE::+yopHEM and 
KIM1001ΔT3SE::+yopHEK were fully 
protected (n=6 mice each), while exposure 
to KIM1001ΔT3SE::+yopHE provided 
partial protection (3 of 10 mice died). Naïve 
mice succumbed to infection (n=8). 
 
The strain expressing YopH, YopE, YopK, and YopM was substantially more 
virulent than the previous strains expressing subsets of these effectors, consistent with the 
fact that this KIM1001ΔT3SE::+yopHEKM strain expresses all effectors previously 
reported to be necessary for full virulence through the subcutaneous model of infection. 
Nevertheless, KIM1001ΔT3SE::+yopHEKM remains attenuated relative to the fully 
wildtype Y. pestis strain KIM1001. KIM1001ΔT3SE::+yopHEKM killed approximately 
50% of infected mice (9 out of 17) at a dose of 103 CFU, indicating a ~100-fold increase 
of LD50 compared to wildtype Y. pestis. Restoring functional copies of the ypkA, yopJ, 
and yopT ORFs to this strain (generating the strain KIM1001ΔT3SE::+yopHEKMAJT) 
fully complemented its virulence defect (Figure 3.2 and Table 3.2). Our ability to recreate 
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this fully virulent “wild-type” strain confirms that the genetic manipulations involved in 
strain construction did not introduce any off-target attenuating mutations. 
Figure 3.2. YopH, YopE, YopK, and YopM are not sufficient for full virulence. 
Subcutaneous infection with 1000 CFU 
KIM1001 (w.t.) (n=12), 
KIM1001ΔT3SE::+yopHEKMAJT 
(complemented) (n=15), or 
KIM1001ΔT3SE::+yopHEKM 
(+yopHEKM) (n=17). Mice infected with 
KIM1001 or with the fully complemented 
strain rapidly succumbed to infection, 
while KIM1001ΔT3SE::+yopHEKM 
killed 9 out of 17 mice with delayed 
kinetics. 
 
YopJ, YopT, and YpkA each contribute to virulence of Y. pestis through the 
subcutaneous route of infection. The attenuation of KIM1001ΔT3SE::+yopHEKM 
relative to KIM1001ΔT3SE::+yopHEKMAJT is strong evidence that at least one of the 
remaining effectors (YopT, YpkA, or YopJ) functionally contributes to virulence in vivo. 
Strains deficient in any one of these effectors are not significantly attenuated (166, 167) 
(and see Table 3.2). To investigate this apparent discrepancy, we generated derivatives of 
the KIM1001ΔT3SE::+yopHEKM strain that included a functional copy of either the 
ypkA, yopT, or yopJ gene in its original locus. The resulting strains 
(KIM1001ΔT3SE::+yopHEKMA, expressing YpkA; KIM1001ΔT3SE::+yopHEKMT, 
expressing YopT; and KIM1001ΔT3SE::+yopHEKMJ, expressing YopJ) were each 
substantially more virulent than KIM1001ΔT3SE::+yopHEKM (Figure 3.3 and Table 
3.2). 
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Figure 3.3. Addition of YpkA, YopT, or YopJ enhances the virulence of a Y. pestis strain 
expressing YopH, YopE, YopK, and YopM. Survival following subcutaneous infection with 
1000 CFU KIM1001ΔT3SE::+yopHEKMA (+yopHEKMA) (n=16), 
KIM1001ΔT3SE::+yopHEKMT (+yopHEKMT) (n=15), or KIM1001ΔT3SE::+yopHEKMJ 
(+yopHEKMJ) (n=26), compared to the survival curves for KIM1001ΔT3SE::+yopHEKMAJT 
and KIM1001ΔT3SE::+yopHEKM from Figure 3.2. KIM1001ΔT3SE::+yopHEKMA killed 14 
out of 16 mice, KIM1001ΔT3SE::+yopHEKMT killed 13 out of 15 mice, and 
KIM1001ΔT3SE::+yopHEKMJ killed 22 out of 26 mice, all with kinetics similar to 
KIM1001ΔT3SE::+yopHEKMAJT. 
 
Curiously, the KIM1001ΔT3SE::+yopHEKMA, KIM1001ΔT3SE::+yopHEKMT, 
and KIM1001ΔT3SE::+yopHEKMJ strains were indistinguishable from one another in 
their degree of virulence. The distinct biochemical activities of YopT, YpkA, and YopJ 
(see Table 3.1) would predict that they are not truly redundant, and may enhance 
virulence through distinct processes. We therefore began to investigate other infection 
outcomes and in vivo endpoints in order to more fully to determine the mechanism by 
which each of these effectors contributes to bacterial fitness. 
YopJ suppresses immune cell recruitment in the liver. Evaluation of liver pathology 
following intravenous infection is a useful method to assay immune cell responses to Y. 
pestis (15, 78, 209), and has several advantages, including simultaneous seeding of 
multiple lesions. This controls for potentially confounding effects of delayed 
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dissemination kinetics in some mutants, and also reduces the variability that can result 
from examining lesions seeded at different times. 
 The Y. pestis KIM1001ΔT3SE::+yopHEKM strain and the strains that 
additionally expressed YpkA, YopT, or YopJ were injected intravenously into mice. 
Livers were collected 48 hours after infection for histopathological analysis. 
KIM1001ΔT3SE::+yopHEKM elicited robust recruitment of immune cells, whereas 
KIM1001ΔT3SE::+yopHEKMAJT, like KIM1001, effectively suppressed accumulation 
of inflammatory cells at foci of bacterial growth (Figure 3.4A-B). The addition of YopJ 
to KIM1001ΔT3SE::+yopHEKM appears sufficient to fully suppress immune cell 
recruitment, as lesions caused by KIM1001ΔT3SE::+yopHEKMJ were indistinguishable 
from those caused by KIM1001. By contrast, neither KIM1001ΔT3SE::+yopHEKMA 
nor KIM1001ΔT3SE::+yopHEKMT suppressed inflammatory cell recruitment relative to 
KIM1001ΔT3SE::+yopHEKM (Figure 3.4A-B). YopJ, therefore, appears to uniquely 
suppress accumulation of immune cells at sites of bacterial replication in vivo. 
 
Figure 3.4 (next page). YopJ suppresses immune cell recruitment to foci of bacterial growth 
in liver tissue. (A) Representative liver sections stained with hematoxylin and eosin from mice 
48 hours after intravenous infection with 103 CFU KIM1001 (w.t.), 
KIM1001ΔT3SE::+yopHEKMAJT (complemented), KIM1001ΔT3SE::+yopHEKMJ 
(+yopHEKMJ), KIM1001ΔT3SE::+yopHEKM (+yopHEKM), KIM1001ΔT3SE::+yopHEKMA 
(+yopHEKMA), or KIM1001ΔT3SE::+yopHEKMT (+yopHEKMT). Strains with a functional 
yopJ allele grow freely in liver tissue without attracting inflammatory cells (top row), in contrast 
to strains deficient in yopJ (bottom row). (B) Severity of inflammation was scored on an arbitrary 
scale (1 = free bacteria with few or no inflammatory cells; 5 = abundant inflammatory cells with 
little or no visible free bacteria; see Methods section for more details). Each data point represents 
the average score for 10 lesions from a single mouse. Representative of two scorings of blinded 
samples.  
  
 72 
 
 
YpkA, YopT, and YopJ are dispensable for bacterial fitness in vivo. Although YpkA, 
YopT, and YopJ each increased virulence of KIM1001ΔT3SE::+yopHEKM by a similar 
magnitude, it is possible that they have different effects on bacterial fitness in vivo. To 
test competitive fitness, we co-colonized mice with one of the combinatorial T3SS 
effector strains described above and a KIM1001 strain carrying a deletion in the xylB 
gene, which provides a neutral marker that allows color-based differentiation of colonies 
on plates containing xylose and neutral red without changing virulence or fitness (K. 
Pouliot and J. Goguen, unpublished). We intravenously infected mice with 5x103 CFU of 
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a 1:1 mixture of KIM1001ΔxylB and KIM1001ΔT3SE::+yopHEKM, 
KIM1001ΔT3SE::+yopHEKMA, KIM1001ΔT3SE::+yopHEKMT, 
KIM1001ΔT3SE::+yopHEKMJ, or KIM1001ΔT3SE::+yopHEKMAJT. After 45 hours, 
the proportion of each effector mutant relative to KIM1001ΔxylB in the spleens of mice 
remained the same as in the input population (Figure 3.5), indicating that none of these 
strains has a severe fitness defect in vivo. By contrast, when the same experiment was 
repeated using a 1:1 mixture of KIM1001ΔxylB and KIM1001ΔT3SE, the bacterial 
population recovered from mouse spleens 45 hours post-infection was 100% 
KIM1001ΔxylB, consistent with the expectation that this avirulent strain would be highly 
susceptible to killing by innate immune cells and thus at a severe competitive 
disadvantage in vivo. 
 
Figure 3.5. YopH, YopE, YopK, and YopM are sufficient for full fitness of Y. pestis in deep 
tissue. Mice were infected intravenously with 5x103 CFUs of a 1:1 mixture of KIM1001ΔxylB 
and KIM1001ΔT3SE::+yopHEKM, KIM1001ΔT3SE::+yopHEKMA, 
KIM1001ΔT3SE::+yopHEKMT, KIM1001ΔT3SE::+yopHEKMJ, or 
KIM1001ΔT3SE::+yopHEKMAJT. The proportion of each mutant strain relative to 
KIM1001ΔxylB was determined in the inoculum and in spleens 45 hours post-infection.  
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Macrophage cell death is induced by the T3SS needle and by YopJ.  The in vivo 
experiments described above demonstrated a novel role for YopJ, YopT, and YpkA in 
enhancing virulence of Y. pestis. YopJ appears to enhance virulence by repressing 
immune cell recruitment to sites of bacterial growth, but YopT and YpkA do not share 
this property. It is therefore unclear how these two effectors contribute to virulence of Y. 
pestis. To address this problem, we turned to in vitro assays to determine how the effector 
proteins of Y. pestis change the nature of interactions between the bacterium and innate 
immune cells. The ability of the Y. pestis T3SS to cause apoptosis in macrophages is well 
established, and is often considered an important function in promoting virulence. We 
therefore examined how various components of the T3SS influenced macrophage cell 
death. 
These in vitro experiments were performed in strains lacking the pgm locus 
required for iron acquisition (see Introduction, page 16) to permit experimentation under 
biosafety level 2 conditions. Immortalized macrophages were infected with the full set of 
strains expressing single effector proteins (JG150ΔT3SE::+yopH, JG150ΔT3SE::+yopE, 
etc.). Macrophage death was measured in real time by monitoring uptake and 
fluorescence of ethidium homodimer, as described ((209) and see Materials and 
Methods). Consistent with previous reports, the T3SS-positive strain JG150 increased 
cell death compared to the pCD1-deficient strain JG152. The strain JG150ΔT3SE, which 
expresses the injectisome and translocon in the absence of effector proteins, also caused 
robust cell death. Although the amount of cell death caused by the JG150ΔT3SE strain 
trended lower than that caused by JG150, the effect did not reach significance (Figure 
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3.6, left). These observations are consistent with published reports that the T3SS needle 
and translocon proteins are sufficient to cause macrophage cell death (209), perhaps due 
to caspase-1 activation via the NLRP3/NLRC4 inflammasome (195). 
 
Figure 3.6. Cytotoxicity of Y. pestis T3SS mutants in immortalized macrophages. C57BL/6 
immortalized macrophages (iMacs) were infected with Y. pestis at an MOI of 1. Loss of cell 
membrane integrity was monitored kinetically by assaying ethidium homodimer uptake and 
quantified by calculating the area under each curve (AUC), as described (Methods and (209)). 
Amount of cell death calculated by AUC was normalized to the amount of cell death caused by 
the T3SS-positive strain JG150 (set to 100%). Left: Y. pestis strains expressing only a single 
T3SS effector. Cell death calculated over 10 hours. Right: Y. pestis strains expressing select 
combinations of T3SS effectors. Cell death calculated over 6 hours. Graphs show the mean and 
standard error for two combined independent experiments, each with n=4. * denotes p<0.05 
compared to JG150 (one-way ANOVA with Dunnett’s correction).  
 
Expression of YopE, YopK, YopM, or YopT alone suppressed cell death 
mediated by the T3SS injectisome, but expression of YopH, YpkA, or YopJ did not 
(Figure 3.6, left). However, YopH, YpkA, and YopJ cannot all simply be passive in this 
system. The observation that the JG150 strain, expressing all seven effectors, causes 
macrophage cell death in spite of the apparently repressive influences of YopE, YopK, 
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YopM, and YopT suggests that at least one of the remaining three effector proteins either 
(i) prevents these effectors from repressing injectisome-mediated cell death, or (ii) 
induces cell death through a distinct pathway that is not susceptible to downregulation by 
these effectors. We next wished to determine which of the remaining effectors – YopH, 
YpkA, and YopJ – were responsible for overcoming this barrier to cell death. 
To determine how these effectors interact when present in combinations, and in 
particular how these emergent properties might influence the virulence phenotypes we 
observed in vivo, we assayed Δpgm derivatives of the same strains expressing four or five 
effectors that were tested for virulence in vivo in Figures 3.2 and 3.3. 
JG150ΔT3SE::+yopHEKM, JG150ΔT3SE::+yopHEKMA, and 
JG150ΔT3SE::+yopHEKMT all failed to induce macrophage cell death, indicating that 
neither YopH nor YpkA is likely to be responsible for the cell death observed for the 
JG150 strain. However, JG150ΔT3SE::+yopHEKMJ induced macrophage cell death as 
strongly as JG150 and the fully-complemented strain JG150ΔT3SE::+yopHEKMAJT 
(Figure 3.6, right). YopJ is known to cause macrophage cell death via caspase-8 signaling 
(17), a distinct mechanism from the NLRP3/NLRC4 activation of caspase-1 thought to 
mediate cell death in response to the injectisome apparatus alone. These results are 
therefore most consistent with hypothesis (ii) above. It is possible that this YopJ-
mediated cell death contributes to the reduced visible recruitment of innate immune cells 
in vivo (Figure 3.4). However, these results do not elucidate a mechanism for YopT- and 
YpkA-enhanced virulence. 
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Development of a bioluminescence-based assay to monitor T3SS dependence of Y. 
pestis survival in co-culture with primary human neutrophils. In addition to 
undermining macrophage function, Y. pestis must overcome the antimicrobial host 
responses mediated by neutrophils. The T3SS is known to be critical for evasion of 
neutrophil killing in vitro (47) (and, to some degree, in vivo (197)). To determine whether 
any of the observed synthetic phenotypes in vivo resulted from differential ability to 
survive neutrophil antimicrobial responses, effector mutants were assayed systematically 
for the ability to survive in co-culture with primary human neutrophils. To facilitate the 
effort of assaying a large number of bacterial strains simultaneously, we developed an 
assay to monitor bacterial survival in co-culture with human neutrophils that is higher-
throughput than plating to measure colony-forming units (CFU), and has the additional 
benefit of providing a readout of bacterial metabolic activity in real time. 
The plasmid pML001 encodes the lux operon from Photorhabdus luminescens, 
which confers bioluminescence to Y. pestis (215). The bioluminescence reaction 
mediated by the lux operon requires the reduced flavin mononucleotide FMNH2 as a 
cofactor (216). Reduction of FMN to FMNH2 occurs as a result of electron transport 
redox reactions during oxidative phosphorylation; FMNH2 then serves as the electron 
donor for the next step in electron transport, releasing its protons to the extracellular face 
of the membrane to maintain the proton motive force. The availability of FMNH2 is 
consequently indicative of an active cellular metabolism and the integrity of the bacterial 
membrane, as the pool of the reduced intermediate is rapidly depleted if either of these is 
interrupted.   
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Figure 3.7. The T3SS requires 
effectors to promote survival of Y. 
pestis in co-culture with 
neutrophils. (A) Relative light units 
(RLU) of JG150L (T3SS+, shaded 
symbols) and JG152L (T3SS-, open 
symbols) in the presence (circles) and 
absence (squares) of primary human 
neutrophils. (B) Same data as in (A), 
analyzed such that the luminescence 
of each replicate in the presence of 
neutrophils is shown as a percentage 
of that replicate’s luminescence in the 
absence of neutrophils at the same 
time point. (C) Luminescence of 
JG150L (T3SS+), JG152L (T3SS-), 
and JG150LΔT3SE (ΔT3SE) in the 
presence of neutrophils; data analyzed 
as in panel B. JG150LΔT3SE is as 
susceptible to neutrophil killing as 
JG152L. Shown: mean and standard 
deviation (symbols) or mean only 
(lines) of 3 replicates. Representative 
of 7 independent experiments. 
 
 
Because bioluminescence from the lux operon requires an intact bacterial 
membrane, it serves as a proxy for determining viability of the bacterial population in 
real time. When bioluminescence of Y. pestis pML001 strains was measured in the 
presence of primary human neutrophils, we found that the luminescent pCD1-deficient 
strain JG152L was much more sensitive to neutrophil killing than JG150L, a strain with a 
functional T3SS (Figure 3.7A-B). A standard CFU plating assay confirmed that the 
decreased luminescence of the T3SS-deficient strain after 4 hours in the presence of 
neutrophils corresponded to a 50-80% reduction in bacterial viability compared to the 
media-only (no neutrophil) condition. 
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YopE and YopH are each sufficient to protect against neutrophil killing of Y. pestis 
in vitro. Although expression of the injectisome without effector proteins is not sufficient 
for virulence in mice, the effector proteins as a group have been shown to be dispensable 
for some effects of the T3SS. For example, the needle and translocon proteins alone are 
sufficient to induce robust cell death in macrophages (209) (and see Figure 3.6). We have 
also demonstrated that a Y. pestis strain expressing the T3SS apparatus is able to prevent 
thrombin-stimulated platelet aggregation, even in the absence of any effector proteins 
(see Chapter 4, Figure 4.4). This was not the case for bacterial survival in the presence of 
neutrophils. JG150LΔT3SE, a luminescent Δpgm strain derived from KIM1001ΔT3SE, 
was as susceptible to neutrophil killing as the pCD1-deficient strain JG152L (figure 
3.7C), indicating that at least one T3SS effector must contribute to the survival of Y. 
pestis in the presence of neutrophils. To determine which of the effector proteins is 
responsible for enhancing bacterial survival, we constructed a set of bioluminescent Y. 
pestis mutants that each carried an in-frame deletion in a single effector protein. 
However, none of these single effector knock-outs was deficient for survival in co-culture 
with neutrophils (figure 3.8A). 
 As no single effector appears to be necessary for survival in the presence of 
neutrophils, we next determined which effectors are sufficient to mediate the T3SS-
dependent protection. Beginning with the effector-less JG150LΔT3SE strain, we used the 
same allelic exchange strategy as described above to individually restore a functional 
ORF for each effector into its original locus. The resulting set of seven strains each 
expressed a functional injectisome and a single effector protein regulated by its 
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endogenous promoter. Using these strains, we found that either YopH or YopE was 
sufficient to rescue the sensitivity of the JG150LΔT3SE mutant, restoring bacterial 
survival to wild-type levels (figure 3.8B-C), suggesting that these effectors are redundant 
for the neutrophil resistance phenotype in this assay. No other effector was capable of 
protecting the JG150LΔT3SE strain from neutrophil killing. 
 
Figure 3.8. YopH and YopE are each sufficient to promote survival of Y. pestis in the 
presence of neutrophils. All luminescence data is analyzed as in Figure 3.6B. (A) Deletion of 
any single effector from JG150L failed to substantially increase bacterial killing in the presence 
of neutrophils. (B and C) Addition of a functional yopH or yopE gene to the JG150LΔT3SE 
genetic background rescues bacterial survival to wild-type levels, while addition of other 
effectors has no effect. Shown: mean and standard deviation (symbols) or mean only (lines) of 3 
replicates. Representative of 2 independent experiments. 
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 The functional redundancy between YopH and YopE in this assay was confirmed 
by constructing a strain carrying in-frame deletions in the ORFs for both of these 
effectors. This strain, JG150LΔyopEΔyopH, was as sensitive to neutrophil antimicrobial 
function as JG150LΔT3SE (Figure 3.9A). The synthetic sensitivity of 
JG150LΔyopEΔyopH is specific to this particular combination of mutations: deletion of 
the yopE ORF in combination with other effectors does not increase bacterial sensitivity 
to neutrophils (Figure 3.9B), presumably because the presence of YopH in these strains 
continues to protect them from neutrophil killing. 
 
Figure 3.9. YopH and YopE are functionally redundant in an in vitro assay for bacterial 
survival in the presence of neutrophils. All luminescence data was analyzed as in Figure 3.6B. 
(A) A strain carrying deletions of both the yopH and yopE genes from the JG150L genetic 
background (ΔyopEH) is as sensitive to neutrophil killing as JG150LΔT3SE (ΔT3SE). (B) 
Deletion of the yopE gene in combination with deletions of yopK (ΔyopEK), yopT (ΔyopET), or 
yopJ (ΔyopEJ) does not interfere with Y. pestis resistance to neutrophil killing. Shown: mean and 
standard deviation (symbols) or mean only (lines) of 3 replicates. Representative of 2 independent 
experiments.  
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Discussion 
 In light of the full virulence of Y. pestis strains deficient in YopJ, YopT, or YpkA, 
we were surprised to find that a strain missing all three of these effectors is significantly 
attenuated for virulence following subcutaneous infection. The simplest explanation for 
this is that two of these three effectors are functionally redundant. If this hypothesis were 
correct, the addition of either effector in the redundant pair to the 
KIM1001ΔT3SE::+yopHEKM background should have restored full virulence, while the 
addition of the third (non-redundant) effector should have had no effect. Instead, all three 
remaining effectors were able to individually increase virulence, although none was able 
to fully restore it to wildtype levels (Figure 3.3). Rather than true redundancy, this result 
suggests that each of these three effectors enhances virulence through some (at least 
partially) unique mechanism. It is possible that each effector contributes roughly 
additively to virulence of Y. pestis, and that the presence of six effectors that include the 
core effector set of YopH, YopE, YopK, and YopM is sufficient to pass some threshold 
of immune subversion that allows robust dissemination and proliferation of Y. pestis in 
vivo. 
 The differential effects of YopJ, YopT, and YpkA on immune cell recruitment 
supports the notion that these effectors are not entirely redundant. Suppression of 
immune cell recruitment is crucial to Y. pestis virulence and dissemination, and the 
central purpose of the T3SS in Y. pestis is to allow bacterial proliferation in vivo by 
undermining antimicrobial responses of immune cells. It was logical, therefore, to 
examine the effect of various effector combinations on immune cell recruitment in the 
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context of Y. pestis infection. We found that YopJ is uniquely important in preventing 
innate immune cell accumulation at bacterial lesions in the liver, a model that is further 
supported by a recent report showing a similar phenotype in a YopJ single deletion strain 
(209). Ratner et al. also found that, when YopM is absent, YopJ is necessary for full 
virulence of Y. pestis following subcutaneous infection. However, the YopM-independent 
role for YopJ in virulence that we report here is a novel finding. 
 Neutrophils help to control the proliferation of Y. pestis (196, 198), and are 
therefore an important target for the type III secretion system in vivo (51, 197, 217). 
Undermining immune signaling and antimicrobial functions of neutrophils is one 
important facet of the general Y. pestis strategy to evade containment by the innate 
immune system, key to its dramatic invasiveness and lethality. Experimental models 
focusing on Y. pseudotuberculosis and Y. enterocolitica have demonstrated that YopH 
and YopE each contribute to T3SS-dependent interference with neutrophil function (45, 
204, 205, 218, 219), but no truly systematic genetic approach has previously been 
employed to define the functional importance of all Y. pestis T3SS effectors in promoting 
bacterial survival in the presence of neutrophils. Consistent with the known importance 
of YopH and YopE in dysregulating neutrophil responses to other species of Yersinia, we 
found that the presence of YopH or YopE was sufficient to allow bacterial survival and 
proliferation in co-culture with neutrophils. This result may partially explain the 
importance of YopH and YopE for virulence in vivo. However, these neutrophil 
experiments failed to demonstrate a role for any of the other, less well-studied effector 
proteins. 
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 YopJ of the Y. pestis T3SS has long been known to induce cell death in 
macrophages (220). This activity has been speculated to contribute to the general 
derangement of immune responses that permits bacterial proliferation and virulence in 
vivo. The work presented here is in agreement with recent reports that, though 
NLRP3/NLRC4-mediated cell death has been shown to occur in response to the needle 
and translocon proteins of the JG150ΔT3SE strain (195, 209), macrophage cell death 
mediated by the wild-type T3SS seems to depend primarily on the activity of YopJ (17). 
 Here, we have established a role for YopT and YpkA in infection, but we cannot 
yet explain how each of these effectors enhances the virulence of the 
KIM1001ΔT3SE::+yopHEKM strain. Interestingly, both YopT and YpkA interfere with 
Rho signaling in mammalian cells. Rho GTPases are also the key host targets of YopE 
activity. The importance of multiple effectors for deranging Rho signaling is not clear, 
though it is possible that differential tissue tropism or effector kinetics may play a role. 
Promising lines of inquiry for these strains include measuring the effect of YopT and 
YpkA on cytokine production in vivo, on the kinetics and magnitude of colonization of 
distal organs following subcutaneous infection, and on the ability of Y. pestis to establish 
and maintain sufficient bacteremia to reliably infect fleas feeding on infected mammals. 
Distinguishing between the infections caused by these different strains will provide 
valuable insight into the functional role of each effector during infection, as well as the 
selective pressures underlying the conservation of these effectors in Y. pestis. 
Genetic analysis of partially redundant systems, even those of only moderate 
complexity such as the seven effectors of the Yersinia T3SS, is difficult to perform in a 
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comprehensive manner. Combinatorial knockouts are the traditional approach to 
identifying functional redundancy, but an unbiased combinatorial approach rapidly 
becomes unfeasible as the size of the system increases. For example, even constructing 
and assaying all 21 possible double knockouts of Y. pestis T3SS effectors is not an 
attractive approach, and there is no guarantee that functional redundancy is limited to 
only two effectors. The “bottom-up” approach we describe here, to identify effector(s) 
that are sufficient rather than necessary for various phenotypes, is perhaps generalizable 
to other complex systems. We have shown that this approach can be particularly effective 
when combined with candidate-based hypothesis testing, as this limits the number of 
combinations that must be examined. Once such strains are generated, they can be 
assayed for multiple phenotypes in both in vitro and in vivo systems. Indeed, the utility 
and sensitivity of this approach is highlighted by the finding that, while 
KIM1001ΔT3SE::+yopHE, KIM1001ΔT3SE::+yopHEM, and 
KIM1001ΔT3SE::+yopHEK are equally avirulent following subcutaneous infection in 
mice, the KIM1001ΔT3SE::+yopHE strain was less able to stimulate protective immune 
responses against subsequent challenge. Further exploration of synthetic phenotypes for 
these combinatorial strains in diverse disease outcomes will allow us to experimentally 
and systematically determine functions of T3SS effectors during infection and to develop 
a more comprehensive and physiological model for the mechanisms by which the T3SS 
of Y. pestis contributes to fitness and transmission of this zoonotic pathogen. 
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CHAPTER IV : Yersinia pestis escapes entrapment in thrombi by 
acivating plasminogen and intoxicating platelets 
 
Preface 
This chapter is adapted from an unpublished manuscript. 
Authors: Samantha G. Palace1, Milka Koupenova2, Olga Vitseva2, Megan K. Proulx1, 
Jane E. Freedman2, and Jon D. Goguen1* 
1Department of Microbiology and Physiological Systems; 2Department of Medicine, 
Division of Cardiovascular Medicine; University of Massachusetts Medical School, 55 
Lake Ave. N, Worcester, Massachusetts 01655, USA. 
 
This chapter is the result of a collaboration with MK and JEF, who consulted with SGP 
and JDG on experimental design and implementation. SGP and MK prepared the 
manuscript. All data was generated by SGP, independently or in collaboration with MK, 
except for the following experiments contributed by co-authors: 
MK performed staining and microscopy for experiments presented in Figure 4.6. 
OV performed electron microscopy for experiments presented in Figure 4.7. 
MKP collaborated with SGP on construction of mutant Y. pestis strains. 
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Introduction 
 Dissemination of Yersinia pestis from a subcutaneous or intradermal infection site 
depends on the outer membrane protease Pla, without which Y. pestis fails to cause 
systemic infection and therefore becomes avirulent by these routes of infection (11, 64, 
65). While Pla has been reported to have several activities, available evidence from in 
vivo studies supports the model that Pla enhances dissemination of Y. pestis from 
peripheral infection sites by activating mammalian plasminogen, which then degrades 
fibrin (77, 78) (see page 9 of the Introduction for a review of the relevant literature). 
 Both plasminogen and fibrin are plasma proteins that belong to the mammalian 
hemostatic system. Upon activation of the clotting cascade composed of serine protease 
zymogens, cleavage of fibrinogen and crosslinking between the resulting fibrin 
monomers supports platelet thrombus formation (67, 221). Platelets, anucleate 
megakaryocyte fragments, form lamellopodia and degranulate upon activation. This 
stabilizes the clot and releases soluble mediators that promote both thrombosis and 
inflammation. Plasmin, generated by cleavage of the zymogen plasminogen, degrades 
fibrin to resolve thrombosis events (67, 68). As described in the Introduction, Y. pestis 
Pla promotes invasiveness by triggering host plasmin to degrade fibrin. The virulence 
requirement for Pla is strong evidence that fibrin deposition would otherwise facilitate 
successful containment of the bacterium by the innate immune system. 
The nature of this fibrin-mediated barrier to bacterial dissemination remains 
unclear. It is possible that fibrinogen simply forms a physical barrier to dissemination, 
enhancing host survival by constraining bacterial diffusion from the site of infection. In 
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addition to mechanical entrapment of bacteria, however, coagulation may also prime or 
promote effective innate immune responses. The hemostatic and immune systems of 
vertebrates share a deep evolutionary entanglement (80, 81, 222). This relationship is 
reflected by extensive functional crosstalk between these two systems, the depth and 
importance of which is becoming increasingly clear. 
Thrombosis has historically been characterized as an aberrant or pathological 
response during infection. In the context of sepsis, for example, activation of endothelial 
cells and disseminated intravascular coagulation is generally considered to increase 
disease severity and contribute to poor patient outcomes (223-225). However, a limited 
amount of controlled thrombosis may be beneficial during infection. Activation of 
platelets, the major cellular component of the hemostatic system, has been shown to 
induce or strengthen immune responses against pathogen-associated molecular patterns 
(PAMPs) (90, 92, 226, 227) and in the context of experimental infection (92, 228-230). 
Several reports have demonstrated that platelets enhance formation of neutrophil 
extracellular traps (NETs) in vivo in response to immune stimuli or infection (90, 231, 
232). Engelmann and Massberg recently coined the term “immunothrombosis” for this 
productive involvement of coagulation in immune response, to distinguish these 
processes from purely pathological thrombosis events (233). 
Work illuminating the functional role of immunothrombosis has so far focused 
primarily on responses to PAMPs and to viral infections, with only a few studies 
examining the role of platelet activation and immunothrombosis in bacterial infection 
(228-230). Because flea-borne transmission of Y. pestis requires dense bacteremia, this 
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pathogen must evade entrapment in thrombi during prolonged circulation in the vascular 
compartment. As a result, Y. pestis virulence presents an unusually clear and tractable 
system for probing the mechanisms that allow bacteremia-causing pathogens to 
undermine immunothrombosis. 
In this work, we demonstrate that plasminogen activation by Pla prevents 
entrapment of Y. pestis in clots in an in vitro thrombosis model. Surprisingly, we also 
found that the type III secretion system (T3SS) of Y. pestis contributes to bacterial escape 
from these in vitro thrombi. The T3SS of Y. pestis intoxicates platelets, preventing 
morphological changes associated with platelet activation in response to a pro-thrombotic 
stimulus. When neutrophils were incorporated into this model, the T3SS decreased NET 
formation and enhanced bacterial survival in platelet thrombi. We speculate that T3SS 
intoxication of platelets may enhance both dissemination and survival of Y. pestis by 
preventing bacterial entrapment in thrombi and by decreasing the effectiveness of 
neutrophil antimicrobial responses. This is the first demonstration of a bacterial T3SS 
successfully targeting platelets to actively inhibit their thrombotic function. 
Results 
Pla mediates Y. pestis escape from platelet/fibrin thrombi in vitro. To determine 
whether plasminogen activation by Pla allows Y. pestis to avoid entrapment in clots, we 
developed an in vitro system to monitor the association of Y. pestis with thrombi. 
Bioluminescent strains of Y. pestis (carrying the lux operon from Photorhabdus 
luminescens on the pML001 plasmid – see page 77) were stirred with purified human 
fibrinogen and plasminogen. Following the induction of thrombus formation by the 
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addition of purified human thrombin (factor IIa), a fibrin clot forms and rapidly becomes 
wrapped around the magnetic stir bar at the bottom of the assay tube. The association of 
the bacterial bioluminescence signal with this clot was monitored in real time to 
determine the spatial distribution of Y. pestis in the assay tube. Pure fibrin thrombi 
sequestered Y. pestis quite efficiently, even in the presence of Pla and plasminogen 
(Figure 4.1 and Movie S4.1). 
 
Figure 4.1. Thrombin-induced fibrinogen clotting in vitro sequesters Y. pestis. Upon addition 
of thrombin to media containing fibrinogen, a clot forms around the magnetic stir bar (dark smear 
at left). The bioluminescence signal from the Y. pestis strain JG150L concentrates in this region, 
indicating that Y. pestis is sequestered in the thrombus. Minimal clot dissolution and bacterial 
escape is observed over thirty minutes, in spite of the presence of plasminogen and the bacterial 
plasminogen activator Pla. 
 
As discussed above, however, pure fibrin clots are not physiological. In vivo, 
platelets are a major functional and structural component of thrombi. We therefore 
adapted this in vitro assay to include platelets, in an effort to more fully recapitulate 
physiological conditions of thrombosis. Freshly isolated washed human platelets were 
combined with bioluminescent Y. pestis at an MOI of 1 in the presence of fibrinogen and 
plasminogen. Thrombin was added to generate fibrin and to activate platelets. The ability 
of platelets to aggregate in response to thrombin was measured as described ((92) and 
Materials and Methods, page 116). 
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In this more physiological system, as in previous experiments, a thrombus 
initially formed following the addition of purified thrombin. The Y. pestis strain JG150L, 
which carries a functional Pla allele, destabilized this initial platelet thrombus and 
reversed platelet aggregation virtually completely within 25 minutes (Figure 4.2, leftmost 
two columns). The strain JG150LplaD86A carries a substitution of alanine for aspartic acid 
at position 86 of Pla, which renders Pla catalytically inactive (70). Unlike JG150L, 
JG150LplaD86A did not destabilize thrombi (Figure 4.2, third column from left). Neither 
JG150L nor JG150LplaD86A had any effect on thrombus stability when plasminogen was 
excluded from the assay buffer. Therefore, destabilization of platelet thrombi by Y. pestis 
requires plasminogen activation by Pla, presumably because fibrin degradation by the 
resulting plasmin undermines the structural integrity of the clot. 
Figure 4.2. Y. pestis destabilization of platelet 
thrombi in vitro depends on Pla and the type III 
secretion system. Washed platelets activated by 
thrombin rapidly form a thrombus that remains 
stable for at least 25 minutes (leftmost column; final 
percentage of aggregation shown). In the presence 
of a Y. pestis strain with functional Pla and T3SS 
alleles, this initial thrombus forms but later 
dissociates during this incubation period (second 
from left). Mutant strains of Y. pestis carrying the 
catalytically inactive allele PlaD86A or lacking the 
T3SS plasmid pCD1 are not able to facilitate 
thrombus dissolution. Each set of shaded points 
corresponds to a single human platelet donor. *** 
denotes p<0.001 (unpaired 2-tailed t test). 
 
The Y. pestis type III secretion system undermines platelet function. As a routine 
control experiment, we repeated the platelet aggregation experiments described above 
using attenuated Y. pestis strains lacking the pCD1 plasmid that encodes the bacterial 
 92 
type III secretion system (T3SS). Surprisingly, T3SS-deficient strains were no longer 
able to interfere with the formation of platelet thrombi, even if they expressed functional 
Pla (Figure 4.2, rightmost two columns). 
 
Figure 4.3. The T3SS facilitates escape of Y. pestis from platelet thrombi in vitro. Thrombin 
(added at t=0) stimulates washed human platelets and purified human fibrinogen to form a 
thrombus that initially collects around the stir bar at the bottom of the assay tube (dark smear at 
left). The bioluminescence signal from the T3SS-positive strain JG150L (top) and the T3SS-
deficient strain JG152L (bottom) initially concentrates in the thrombus that collects around the 
stir bar, but only the T3SS-positive strain JG150L efficiently re-disperses into solution following 
aggregation. Representative of 3 biological replicates from independent platelet donors. 
 
The T3SS-dependent ability of Y. pestis dissociate platelet thrombi correlated 
with the ability of Y. pestis to escape containment by these clots. When monitored by 
bioluminescence as above, we found that the T3SS-positive strain JG150L initially 
became incorporated into the platelet thrombus that collected around the stir bar at the 
bottom of the assay tube, but escaped into solution within thirty minutes (Figure 4.3, top, 
and Movie S4.2). By contrast, the T3SS-deficient strain JG152L remained entrapped in 
the platelet thrombus for the duration of the experiment (Figure 4.3, bottom, and Movie 
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S4.3), despite its functional Pla allele and the presence of purified human plasminogen in 
the assay buffer. We therefore sought to understand the basis for pCD1-dependent 
thrombus destabilization. 
 The effector proteins the T3SS delivers into the cytosol of host cells exert a wide 
array of activities, including derangement of signaling pathways and of the actin 
cytoskeleton. (See page 59 for a description of the known and putative activities of the Y. 
pestis T3SS effectors.) Because each of the effectors has distinct biochemical activities 
and host cell targets, we reasoned that identifying the effector(s) responsible for platelet 
intoxication could elucidate the mechanism by which the Y. pestis T3SS interferes with 
platelet aggregation. 
We first tested the ability of various Y. pestis strains to prevent aggregation by 
intoxicating platelets prior to the addition of thrombin. When platelets and the T3SS+ 
strain JG150L were incubated together for ten minutes prior to thrombin activation, 
intoxication of the platelets was so profound that platelets appeared totally unresponsive 
to the thrombin agonist. No platelet aggregation was observed under this condition 
following the addition of thrombin, and platelets remained free for the duration of the 
experiment (Figure 4.4A). The JG152L strain lacking pCD1 did not prevent platelet 
aggregation, showing that the T3SS apparatus as a whole was required for inhibiting 
platelet aggregation in response to thrombin. However, JG150LΔT3SE3, which expresses 
a functional injectisome apparatus but lacks all seven of the effector proteins, inhibited 
                                                             
3 I have used descriptive strain names such as this one to enhance readability. For full genotypic 
information and formal strain designations, see Table S1.1 (page 118). 
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thrombus formation as effectively as the T3SS+ JG150L strain when incubated with 
platelets for 10 minutes prior to thrombin stimulation (Figure 4.4A). 
 
Figure 4.4. T3SS effectors are dispensable for preventing, but not reversing, platelet 
thrombus formation. The requirement for T3SS effector proteins varies with the relative 
kinetics of platelet intoxication and thrombin activation. (A) Co-incubation of platelets with the 
T3SS-positive strain JG150L (+T3SS) at MOI=1 for 10 minutes prior to stimulation with 
thrombin prevents platelet aggregation. This mechanism of undermining platelet response 
requires the T3SS apparatus, but does not require effector proteins. The pCD1- strain JG152L (-
T3SS) does not prevent aggregation, whereas the JG150LΔT3SE strain (ΔT3SE), which lacks all 
seven effector proteins, prevents platelet aggregation as effectively as JG150L. * denotes p < 0.05 
(paired t test). (B) Addition of Y. pestis (MOI=1) to thrombin-activated platelets already 
beginning to aggregate. Reduced aggregation in this assay requires active reversal of thrombus 
formation, rather than the prevention of platelet activation shown in panel A. The T3SS apparatus 
of the ΔT3SE strain is not sufficient for this activity, though expression of YopH or YopE alone 
fully recapitulates the T3SS-positive phenotype. * denotes p < 0.05 (paired 2-tailed t test; 
unpaired for +T3SS vs. ΔT3SE to allow calculation of p from measures with equal differences). 
 
When Y. pestis and platelets are mixed prior to stimulation, effector proteins are 
not required to prevent platelet aggregation in response to thrombin. However, we 
reasoned that T3SS-mediated dissociation of aggregating platelets that had already been 
activated (e.g. in Figure 4.3, top) might be a more difficult process requiring additional 
T3SS components. To specifically measure bacterial escape from a platelet thrombus, we 
initiated clot formation by adding thrombin to washed platelets in the presence of 
fibrinogen and plasminogen, and added Y. pestis strains to the system only when clots 
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began to form 2-4 minutes later. This approach allowed us to define the bacterial factors 
required for thrombus dissolution, as opposed to preventing thrombus formation. As in 
the previous experiments, JG150L reversed platelet aggregation while JG152L did not, 
indicating that pCD1 was required for thrombus destabilization under these conditions 
(Figure 4.4B, leftmost two columns). In this assay, however, the JG150LΔT3SE strain 
did not phenocopy the JG150L strain. JG150LΔT3SE failed to dissolve the thrombus 
formed by thrombin-stimulated platelets (Figure 4.4B, third column from left). Therefore, 
thrombus prevention and thrombus dissolution mediated by the Y. pestis T3SS likely 
occur by distinct mechanisms, and the clot dissolution shown in Figure 4.3 (and Movie 
S4.2) requires the action of at least one effector protein. 
To determine which of the effectors is responsible for this phenotype, we 
measured the ability of Y. pestis strains expressing single effector proteins to reverse 
platelet aggregation using the same protocol described above. The tyrosine phosphatase 
YopH and the GTPase activating protein YopE were each sufficient to mediate full 
dissolution of platelet thrombi. Surprisingly, each of the remaining effector proteins also 
partially rescued the JG150LΔT3SE phenotype (Figure 4.4B). 
The Y. pestis T3SS inhibits formation of neutrophil extracellular traps (NETs) in 
platelet thrombi. Neutrophils and platelets communicate both in the circulation, where 
they form small heterotypic aggregates (92, 93), and in thrombi (86, 234). Fibrin has also 
been shown to increase the survival and effectiveness of neutrophils responding to Y. 
pestis infection (235). To test whether neutrophils would affect platelet aggregation or 
bacterial survival in vitro, we adapted the in vitro thrombosis model to include primary 
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human neutrophils. Bioluminescence of the T3SS-deficient strain JG152L decreased 
significantly in the presence of neutrophils, indicating reduced viability. Consistent with 
previous reports ((47) and Figure 3.7), this sensitivity to neutrophils was not observed in 
the presence of a functional T3SS. Bacterial killing in this assay is attributable primarily 
to neutrophil function, as neither fibrinogen aggregation nor platelets were sufficient to 
reduce bioluminescence of JG152L (Figure 4.5).  
 
Figure 4.5. Incorporation of neutrophils into platelet thrombi results in reduced survival of 
T3SS-deficient Y. pestis. Bioluminescent strains of Y. pestis JG150L (T3SS+) and JG152L 
(T3SS-) were incubated stirring in siliconized glass tubes with thrombin, fibrinogen, 
plasminogen, and other components as specified. Bioluminescence was imaged as in Figures 4.1 
and 4.3. Total bioluminescence was quantified for each frame as described (see Methods, page 
116) and normalized to the strength of the luminescence signal at time 0 (defined as 100%). 
Bacterial luminescence (a proxy for viability) is independent of the T3SS in thrombi containing 
fibrinogen (A) or fibrinogen and platelets (B), but inclusion of neutrophils decreases viability of 
T3SS-deficient Y. pestis irrespective of the presence of platelets (C and D). Shown: mean and 
SEM for JG150L (solid line, light shading) and for JG152L (dashed line, dark shading) from 2 
(C) or 3 (A, B, D) independent experiments.  
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Neutrophils have an arsenal of antimicrobial activities, including phagocytosis, 
production of reactive oxygen species, and degranulation to release pro-inflammatory 
signaling molecules and directly bactericidal components. Platelet/neutrophil interactions 
seem to be particularly important in inducing formation of neutrophil extracellular traps 
(NETs) (90, 231, 236). We observed robust NET formation in platelet thrombi in the 
presence of JG152L (Figure 4.6B). By contrast, the presence of the Y. pestis T3SS in 
strain JG150L reduced the abundance of NETs in the thrombus (Figure 4.6A). 
 
Figure 4.6. The Y. pestis T3SS reduces NET formation of neutrophils in platelet thrombi. 
Thrombi containing fibrinogen, platelets, neutrophils, and Y. pestis JG150L (T3SS+) or JG152L 
(T3SS-) were fixed 13 minutes after thrombin stimulation, stained, and imaged by confocal 
microscopy (see Methods, page 117). NETs are visible as large smears of DAPI (blue), while 
globular DAPI staining denotes intact nuclei. (A) NET formation in platelet thrombi including 
JG150L is limited. (B) Neutrophils in thrombi including JG152L form extensive NET structures 
that are closely associated with platelets. Green: α-CD41a FITC (platelets), red: α-CD66b APC 
(neutrophils), blue: DAPI (DNA). 
 
The Y. pestis T3SS is known to contribute to bacterial survival in co-culture with 
primary human PMNs ((47) and Figure 3.7) via the action of YopH and YopE (Figure 3.8 
and 3.9). As these same effector proteins interfere with platelet function (Figure 4.4B), 
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we have not yet developed an experimental system to distinguish between the effects of 
neutrophil and platelet intoxication on NET formation. Note, therefore, that direct 
interaction between the T3SS and neutrophils likely plays an important role in reducing 
the bacterial killing and NET formation shown in Figures 4.5 and 4.6. In particular, YopE 
is known to inhibit Rac2-mediated ROS production in neutrophils (204), a key mediator 
of NETosis (237). However, the established role for platelets in activating neutrophil 
functions and NETosis (90) is highly suggestive, and warrants further investigation. 
Platelet intoxication by the Y. pestis T3SS inhibits platelet morphological changes 
associated with activation. Activated platelets undergo profound morphological 
changes, including the formation of extensive lamellipodia that increase thrombus 
stability in vivo (238). We examined thrombi containing fibrinogen, platelets, neutrophils, 
and Y. pestis by scanning electron microscopy to determine whether T3SS-mediated clot 
destabilization correlates with reduced morphological changes in platelets. 
We found that intoxication of platelets by the Y. pestis T3SS limits the extensive 
formation of branched lamellipodia that typically characterize thrombin-activated 
platelets (see scanning electron micrographs in (92)). Platelets dissociated from a 
thrombus by JG150L have an elongated, but not highly branched, morphology when 
visualized by scanning electron microscopy (Figure 4.7A and C) or by phase contrast 
microscopy (not shown). This is distinct from the rounded morphology of resting 
platelets that were not exposed to thrombin or to Y. pestis (see, for example, scanning 
electron micrographs in (92)). When aggregation was performed in the presence of the 
JG152L strain, platelets underwent dramatic morphological changes (Figure 4.7B and D) 
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Discussion 
This work supports the model that Pla activates host plasminogen in vivo, 
promoting host fibrinolysis rather than thrombosis during infection (77). The release of Y. 
pestis from destabilized platelet thrombi is a novel observation. Pla is known to enhance 
invasiveness of Y. pestis and to support the bacteremia cause by this pathogen. Perhaps 
one mechanism by which Pla promotes virulence is by preventing Y. pestis from 
becoming trapped in thrombi, either by inhibiting platelet aggregation altogether or by 
permitting thrombus dissolution. 
The involvement of the T3SS in deranging platelet function suggests that current 
models of T3SS function during infection may need to be expanded. The T3SS of 
Yersinia is known to be particularly important in undermining phagocytosis and other 
antimicrobial functions of macrophages and neutrophils (44-47, 51), but the complete 
range of target cell types is not known. This is the first example of any bacterial T3SS 
targeting platelets, though it seems likely that the absence of previous reports simply 
reflects the relative rarity of bacteria/platelet interaction studies. The apparent adaptations 
of Y. pestis to undermine platelet activation lends credibility to the hypothesis that 
platelets represent an important barrier to the fitness and transmission of bacteria in the 
vascular compartment. The prevalence of type III secretion systems in Gram-negative 
pathogens suggests that T3SS-dependent subversion of platelet responses may be a 
conserved strategy among blood-borne Gram-negative pathogens, especially in light of 
the apparent dispensability of T3SS effector proteins (Figure 4.4A). 
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In vitro, the effectors of the Y. pestis T3SS are able not only to prevent thrombus 
formation, but also to dissociate thrombi once formed. Although the dissolution of large, 
established thrombi by Y. pestis is unlikely to take place in vivo, it is a dramatic and 
intriguing feat of host cell manipulation by the T3SS. We do not understand the 
mechanism by which five effector proteins with disparate biochemical activities (YopK, 
YopM, YpkA, YopT, and YopJ) are able to mediate partial dissolution of platelet 
thrombi. However, YopH and YopE have both been reported to derange actin 
cytoskeleton remodeling (see Table 3.1), which may inhibit platelet function by 
interfering with degranulation, by frustrating cell morphology changes associated with 
activation (as seen in Figure 4.7A and C), or both. It is particularly intriguing to note that 
lamellipodia formation in activated platelets requires Rac1 (238), a known target of YopE 
and other effectors. 
Platelets have been reported to have direct antimicrobial effects and to enhance or 
activate antimicrobial functions of other immune cell types, including neutrophils (88). 
We do not yet know the extent to which platelet activation contributes to effective 
immune responses in the context of Y. pestis infection, though the appearance of NETs in 
thrombosis is suggestive, as are previous reports that link thrombosis to enhanced innate 
immune responses to Y. pestis (78, 235). Future work will focus on exploring this link 
mechanistically and on testing the functional importance of platelet immune responses in 
vivo, using experimental models of thrombocytopenia and a genetic model to prevent 
platelet/fibrinogen interactions (239). 
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CHAPTER V : Discussion 
In addition to being one of the largest historical threats to human health and an 
ongoing concern for bioterrorism, Y. pestis is an extremely effective model organism for 
studying bacterial pathogenesis. Laboratory infections in mouse and rat models are 
simple, as Y. pestis is a natural pathogen of rodents. Progression of the disease is broadly 
similar in mice and in humans, allowing data from experimental infection models to be 
translated to human health fairly easily. Crucially, Y. pestis is also a genetically tractable, 
relatively fast-growing member of the Enterobacteriaceae family. Genetic techniques in 
Y. pestis are nearly as advanced as in E. coli, making Y. pestis an attractive model system 
for genetic approaches to discover bacterial determinants of virulence. 
 The pathogenesis of Y. pestis is particularly interesting as a model for innate 
immune evasion. As a vector-borne pathogen, Y. pestis is under tremendous selective 
pressure to escape containment by the innate immune system and to cause systemic 
disease: only by maintaining dense bacteremia can Y. pestis ensure flea colonization and 
thus transmission. The remarkable invasiveness of Y. pestis is only possible because of 
the concomitant total failure of the innate immune system to contain the infection. 
Determining the mechanisms that allow Y. pestis to proliferate in mammalian tissue and 
evade innate immune responses is key to understanding the infection biology of Y. pestis. 
This system also provides a broader opportunity to understand basic functions of innate 
immunity and the general pathogenesis of invasive bacterial infections. 
We set out to systematically test every gene in the Y. pestis genome for 
importance during mammalian infection. Tn-seq directly measures the fitness cost of 
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mutations and has a large dynamic range, and is therefore one of the best available tools 
for the acquisition of functional genomic datasets. Our Tn-seq analysis of Y. pestis during 
murine infection found that, in addition to many previously characterized virulence 
determinants, Y. pestis requires a diverse array of biosynthetic pathways and nutrient 
importers for full fitness in mice. Most of these are not required during in vitro growth on 
rich media. Nutritional limitation in mammalian tissue to restrict bacterial proliferation is 
a known strategy of immune defense, particularly in the case of metal sequestration 
(240). However, our results demonstrate that the nutritional stress experienced by 
bacteria in deep tissue is more diverse than is often recognized. In the case of Y. pestis, 
fitness in vivo specifically requires machinery for the biosynthesis or acquisition of 
aromatic amino acids, branched-chain amino acids, glucose, and nucleotide precursors, in 
addition to the siderophore system known to be required for iron acquisition. This dataset 
underscores the functional importance of these restrictions in driving pathogen evolution. 
Intriguingly, bacterial adaptations to this nutrient limitation may not be restricted to direct 
import or biosynthesis of limiting nutrients. Inflammation has recently been shown to 
create nutritionally favorable environments for Salmonella (241, 242) and for 
Mycobacterium tuberculosis (B. Mishra and C. Sassetti, under review). It is possible that 
the massive proliferation of Y. pestis in lymphoid tissue, and the cell death induced by the 
Y. pestis T3SS, may play a similar role. 
The initial Tn-seq approach I present here represents only the most 
straightforward application of increasingly low-cost “omics”-level technologies to 
acquire comprehensive, unbiased information for addressing outstanding questions about 
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bacterial pathogenesis. Performing the Tn-seq screen in more targeted, defined conditions 
– e.g., in co-culture with neutrophils or other immune cell types, in nutritionally defined 
media such as SNM, in pulmonary rather than intravenous infection, and so on – could 
provide more mechanistic information about the in vivo pressures that are responsible for 
fitness phenotypes in vivo. Tn-seq is also a powerful tool for genetic interaction studies. 
Assaying transposon libraries constructed in a mutant genetic background is an unbiased 
approach to finding synthetic fitness phenotypes under conditions of interest. This 
strategy could be especially useful to supplement the candidate-based approach for 
determining interactions between effector proteins of the T3SS presented in Chapter III. 
Comprehensively probing the Y. pestis genome – or even the pCD1 plasmid – for genes 
that enhance bacterial survival in the presence and absence of various T3SS effectors 
could provide more information regarding the immune pressures that each effector 
combats. 
The advent of unbiased large-scale technologies for measuring diverse host cell 
metrics such as transcriptional profiles, protein abundance, and protein stability could 
also be applied to this system to define the functions of T3SS components in a more 
detailed, functional way than has previously been possible. These approaches would be 
particularly powerful when combined with the combinatorial mutations of T3SS effectors 
presented here. To study the effects of a particular T3SS effector on host cells, it is not 
uncommon to directly express the effector in host cell lines via transfection (e.g. (50, 191, 
194)). The panel of T3SS mutants constructed in Chapter III, however, allows effectors to 
be studied singly or in defined combinations in the context of a functional injectisome 
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and active bacterial infection. This has many advantages. Protein levels of the effector(s) 
inside the target cell will at least more closely approximate the levels that are translocated 
during active infection with wild-type strains. Delivery by the T3SS needle and 
translocon allows the impact of effector signaling to be assessed in the context of host 
cell responses to the T3SS apparatus itself, which has been shown to mediate cell death 
and to trigger cytokine production in bone marrow-derived macrophages (Chapter III and 
(209)). The presence of live bacteria in these infections will also more fully recapitulate 
the environment in which effectors must function in vivo, as live Y. pestis bacteria in the 
system presumably produce a variety of PAMPs and DAMPs that alter the functional 
profile of immune cells. Of particular interest is whether transcriptomic and proteomic 
investigation of host cells intoxicated with these T3SS mutant strains might give insight 
into the mechanism that underlies the contribution of YpkA and YopT to Y. pestis 
virulence that I report here. These additional in vitro experiments may be particularly 
useful when combined with the additional in vivo experiments proposed in the discussion 
section of Chapter III. 
Improving the design of in vitro assays to make them more physiologically 
relevant is a guiding principle of this work. I began this process in response to the in vivo 
nutrient limitation observed in the Tn-seq dataset. To more fully understand the 
requirement for nutrient importers in vivo, I developed Serum Nutritional medium 
(SNM), a new defined medium for Y. pestis growth which contains physiological levels 
of amino acids, glucose, and salts. Nutrition-related in vivo growth phenotypes of Y. 
pestis can be observed in this medium, even if they are not found in standard complex 
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growth media. This is likely because SNM mimics in vivo fitness pressures on Y. pestis, 
while complex culture media that have been designed to maximize bacterial growth in 
vitro tend to provide a much more permissive environment than is actually present during 
infection. In general, the use of more physiological growth media in place of traditional 
complex media could identify novel bacterial functions required during infection. Some 
of these functions may even prove to be druggable targets for the development of new 
antimicrobial strategies, though drugs targeting nutritional pathways may be prone to act 
through bacteriostatic, rather than bactericidal, mechanisms. 
Since the design of this new media, my focus on developing more “in vivo-like” 
assays has expanded to include the incorporation of diverse host cell types and/or plasma 
components into functional assays for bacterial fitness. Our work on interactions between 
Y. pestis and platelets in vitro stems directly from this strategy. Platelets, a canonical 
member of the hemostatic system, are increasingly appreciated as mediators of 
inflammation and immunity in the context of infection (88). Their importance in 
mediating infection outcomes has been demonstrated especially elegantly in several 
recent papers by van der Poll and colleagues in the context of controlling Streptococcus 
pneumoniae and Klebsiella pneumoniae infections (228, 230). While the role of platelets 
in immunity is widely accepted in the hemostasis and thrombosis literature (e.g. (86)), the 
bacterial pathogenesis field has been slow to adopt the model of platelets as immune 
mediators. Because platelets are highly abundant in the vascular compartment where Y. 
pestis proliferates, and because of the established importance of Y. pestis derangement of 
the hemostatic system, we designed an in vitro assay to determine the effects of Y. pestis 
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on platelet function. We found that Y. pestis undermines platelet aggregation in response 
to thrombin stimulation, and that this requires both plasminogen activation by the 
bacterial Pla protease and intoxication of platelets by the type III secretion system. This 
was the first report that platelets are a target for effector translocation by the T3SS of any 
Gram-negative pathogen. The observation that the T3SS and the Pla plasminogen 
activator work together to reduce thrombosis is particularly important in light of the 
tremendous selective pressure for Y. pestis to maintain a high titer of free bacteria in the 
vasculature to ensure colonization of fleas taking a small blood meal. It is interesting to 
note that, when Y. pestis was pre-incubated with platelets prior to activation with 
thrombin, none of the T3SS effector proteins were required to prevent thrombus 
formation; the T3SS injectisome apparatus was sufficient for this activity. This activity 
may therefore be conserved in T3SSs of other pathogens, though this remains to be 
tested. 
Over time, in vitro systems for studying Y. pestis pathogenesis have quite 
naturally shifted to be more convenient for the researcher. The inclusion of chemically 
undefined cell extracts in growth media speeds division of Y. pestis, allowing 
experiments to be performed more quickly; cell lines can be kept alive indefinitely, 
allowing for in vitro interaction studies with bacteria (or bacterial components) to be 
performed relatively cheaply, and with short notice; the scope of in vitro work on 
Yersinia pathogenesis has narrowed, perhaps unintentionally, to focus primarily on 
interactions with macrophages and macrophage-like cell lines, driven by their 
experimental tractability and the proven track record of these systems in generating clean 
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datasets and robust phenotypes. These studies have provided a wealth of information that 
forms the foundation of our current understanding of Yersinia pathogenesis. The use of 
defined, reductionist systems for studying Y. pestis adaptations to the host environment is 
appealing, as it provides more mechanistically interpretable information than in vivo 
experimentation alone. However, the universe of theoretically discoverable information is 
limited in these simplified systems. As we begin to test the effects of more and more host 
environment factors on Y. pestis physiology and pathogenesis, it is unlikely that every 
factor we test will provide functionally important insight into Y. pestis behavior during 
mammalian infection. Nevertheless, it is an effort worth undertaking. The design and 
implementation of more diverse in vitro assays is crucial in developing a comprehensive 
picture of the host/pathogen interactions that determine infection outcomes in vivo. 
Here, we have shown that the nutritional composition of the host growth 
environment has a profound effect on the genes required for bacterial fitness, that 
interactions between T3SS effectors measurably modulate their individual contributions 
to virulence, and that platelets – a formerly neglected cell type for Y. pestis pathogenesis, 
despite their abundance in the vascular compartment – likely represent a substantial 
barrier to bacterial virulence that Y. pestis must actively overcome. I have generated a set 
of tools that allowed us to demonstrate a novel role for the YopT and YpkA effectors 
during Y. pestis infection, and these tools will accommodate further systematic genetic 
analysis of Y. pestis determinants responsible for various phenotypes related to virulence 
and transmission. Combining the rational design of in vitro assay systems, the validation 
of in vitro phenotypes with in vivo infection models that mimic the natural infection 
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route, and systematic genetic analyses is a generalizable approach to extending existing 
models of bacterial pathogenesis, both for Y. pestis and for other bacterial threats to 
human health. The work presented here is a foundation for understanding the selective 
pressures that have shaped the evolution of Y. pestis as a fulminant invasive pathogen and 
a vector-borne zoonosis, and builds on existing mechanistic models of Y. pestis evasion 
of mammalian innate immune responses. 
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APPENDIX S1: Materials and Methods 
Bacterial strains and growth conditions. Y. pestis strains are presented in Table S1.1. 
Unless otherwise specified, Y. pestis strains were cultured in the rich medium TB, 
prepared to maximize plating efficiency as previously described (243). Additional 
experiments in Chapter II were performed in the defined media PMH2 (157). For in vitro 
experiments involving interaction with macrophages, neutrophils, or platelets, Y. pestis 
strains were cultured in defined Serum Nutritional Medium (SNM) (144). All Y. pestis 
cultures were supplemented with 2.5 mM CaCl2 to suppress type III secretion. Where 
appropriate, media were supplemented with 100 μg/ml ampicillin, 25 μg/ml zeocin, or 25 
μg/ml diaminopimelic acid. 
Construction and complementation of nonpolar mutant strains of Y. pestis. Unless 
otherwise specified, all Y. pestis mutants were constructed via allelic exchange using the 
E. coli donor strain β2155 ((244), gift from B. Akerley) and the suicide vector pRE107 
((245), gift from D. Schifferli). Primers are listed in Table S1.2. Deletion mutants for 
each gene were constructed by amplifying flanking homology to the gene using primer 
pairs A+B and C+D, hybridizing the resulting fragments, and cloning this “stitched” 
product into the pRE107 plasmid before proceeding with allelic exchange as described 
(245). The allele for the catalytic point mutant PlaD86A was constructed by site-directed, 
ligase-independent mutagenesis (SLIM) as described (246) using the primers 
PlaD86A_1-4 (Table S1.2; substitution in bold). This allele was then cloned into pRE107 
using the primers pla-A and pla-B (Table S1.2) and introduced into Y. pestis by allelic 
exchange as above. 
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In Chapter II, mutations were complemented by cloning the wild-type gene under 
control of its native promoter between the KpnI and XbaI sites of the low copy-number 
plasmid pZS*13luc (247); specifics of these constructions can be found in Text S1 of 
(144). Complementation of T3SS mutants in Chapters III and IV was performed in situ, 
using pRE107-based allelic exchange to replace each deleted gene with a wild-type copy. 
Transposon mutagenesis, Tn-seq library construction, and Tn-seq data analysis. 
Experimental details of library generation, selection, preparation for Illumina sequencing, 
and sequence read processing are available in Text S1 of (144). Raw sequence reads are 
available in the NCBI Sequence Read Archive (SRA, 
http://www.ncbi.nlm.nih.gov/Traces/sra) under the BioProject PRJNA240677, accession 
numbers SRX483428 (reference in vitro library), SRX483566 (replicate in vitro library), 
and SRX483575 (in vivo library). Details of fitness and statistical analysis have been 
reproduced from Text S1 of (144) in the addendum to Chapter II (page 50). 
Animal infections. All animal infections were conducted in conformity with the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health, and with 
the review and approval of the UMass Medical School Institutional Animal Care and Use 
Committee (IACUC).  
C57BL/6 and BALB/C mice were infected as indicated. All bacterial cultures 
used for inoculation were grown at 37°C on TB agar (TB medium with 1.5% agar) 
containing 2.5 mM CaCl2 for one overnight prior to infection. Bacterial cells were diluted 
in infection-grade phosphate-buffered saline (PBS) to the desired concentration. In every 
case, the number of viable bacteria present in each dose was verified by dilution plating 
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of the inoculum. Mice were monitored every twelve hours for signs of illness such as 
ruffled fur, shallow breathing, limping, reluctance to move, and swollen lymph nodes. 
Competition experiments of PtsG mutants in vivo and in vitro. Mice were sacrificed 2 
h or 42 h following co-infection with 3x103 CFU of a 1:1 mixture of KIM1001 and 
KIM1001ΔptsG. Spleens were removed and homogenized in 0.5 ml sterile PBS. 
Dilutions were plated on TB agar containing 2.5 mM CaCl2, 1% glucose, and 50 μg/ml 
tetrazolium red. On this medium, the wild-type strain KIM1001 forms white colonies, 
while colonies of KIM1001ΔptsG are purple (248).  In vitro competition experiments 
were performed by mixing JG102 and JG102ΔptsG 1:1 and plating cultures on TB agar 
containing 2.5 mM CaCl2, 1% glucose, and 50 μg/ml tetrazolium red after 0 h or 42 h of 
continuous log-phase growth at 37°C. The fraction of JG102ΔptsG colonies was 
determined by calculating the fraction of purple colonies on these dilution plates. 
 Because the JG102 strain and the complemented strain 
JG102ΔptsG(pZS*13luc::ptsG) both ferment glucose, both form white colonies on TB 
agar supplemented with 1% glucose and 50 μg/ml tetrazolium red. In vitro competition 
experiments with the complemented strain were therefore performed against the control 
strain JG102ΔxylB(pZS*13luc) cultured in the presence of 100 μg/ml ampicillin. 
Dilutions were plated on TB agar supplemented with 2.5 mM CaCl2, 1% xylose, and 30 
μg/ml neutral red after 0 h or 42 h of continuous log-phase growth at 37°C. On these 
plates, the complemented strain JG102ΔptsG(pZS*13luc::ptsG) forms white colonies and 
the control strain JG102ΔxylB(pZS*13luc) forms red colonies. The fraction of 
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JG102ΔptsG(pZS*13luc::ptsG) colonies was determined by calculating the fraction of 
red colonies on these dilution plates. 
 Change in growth rate was determined by plotting the natural log of the ratio of 
the ptsG mutant to the wild-type strain over time and calculating the slope by linear 
regression. Absolute change in growth rate was applied to the measured growth rate for 
the wild-type strain to determine mutant growth rates. 
Histological analysis of T3SS mutants in liver tissue. Mice were sacrificed 48 hours 
after intravenous infection with 103 CFUs. Livers were removed, fixed in 10% neutral-
buffered formalin, and embedded in paraffin for sectioning and staining. Samples were 
randomized and 10 lesions from each mouse were scored, blinded, for severity of 
inflammation in bacterial lesions. The following scale was used for scoring: 1 = free 
bacteria with few or no inflammatory cells; 2 = some inflammatory cells present, but free 
bacteria fill the majority of the lesion area; 3 = lesion area is split approximately equally 
between inflammatory cells and bacteria; 4 = some free bacteria are visible, but 
inflammatory cells fill the majority of the lesion area; 5 = abundant inflammatory cells 
with little or no visible free bacteria. Scoring was performed twice on scrambled, blinded 
samples to ensure results were consistent. 
Competition experiments of T3SS mutants in vivo. Mice were sacrificed 
approximately 45 hours after intravenous infection with 5x103 CFUs of a 1:1 mixture of 
KIM1001ΔxylB and various T3SS mutants. Spleens were removed and homogenized in 
0.5 mL sterile PBS. Dilutions were plated on TB agar containing 2.5 mM CaCl2, 1% 
xylose, and 30 μg/ml neutral red. On these plates, KIM1001ΔxylB forms red colonies, 
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while the various xylB-positive T3SS mutants form white colonies. The relative 
abundance of each strain was determined by calculating the fraction of white colonies on 
these dilution plates. 
Macrophage cell death experiments. Macrophages were monitored for cell death by 
ethidium homodimer (EthD1) fluorescence, as described (209). Upon loss of integrity of 
the cell membrane, EthD1 penetrates the cell, binds DNA, and emits red fluorescence. 
EthD1 uptake is monitored kinetically by plate reader as relative fluorescence units 
(RFU) and quantified by calculating the area under each curve (AUC). 
8x104 immortalized murine macrophages from C57BL/6 mice (a gift from K. 
Fitzgerald) were infected with 8x104 CFU of various Y. pestis strains grown to mid-log 
phase in SNM supplemented with 2.5 mM CaCl2. Macrophages and bacteria were added 
to flat-bottomed 96-well plates with black sides in DMEM supplemented with 10% 
ΔFBS, 10 mM HEPES, and 2 μM ethidium homodimer. Plates were centrifuged at 400 
rpm for five minutes, sealed, and incubated at 37°C in a Synergy H4 microplate reader. 
Ethidium homodimer fluorescence at 645 nm following excitation at 530 nm was 
monitored at minimum read intervals. Ethidium homodimer uptake data was analyzed by 
calculating the area under the curve (AUC) for the increasing fluorescence signal and 
subtracting the AUC of control wells containing uninfected macrophages. 
Survival of T3SS in co-culture with primary human neutrophils. Whole blood was 
collected from healthy adult human volunteers in compliance with protocols reviewed 
and approved by the University of Massachusetts Medical School Institutional Review 
Board (IRB). Neutrophils were isolated from whole blood on a gelatin gradient as 
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described (249). Y. pestis viability assays were performed in opaque white flat-bottomed 
96-well plates that had previously been coated for 1 hour with 10 μg/mL fibrinogen in 
phosphate-buffered saline (PBS) and washed twice with PBS. 5x105 neutrophils were 
infected with luminescent strains of Y. pestis at MOI 0.1 in SNM supplemented with 2.5 
mM CaCl2, 100 μg/ml ampicillin, and 4% normal human serum. Plates were centrifuged 
at 400 rpm for five minutes, sealed, and incubated at 37°C in a Synergy H4 microplate 
reader. Bacterial luminescence was monitored in real time using minimum read intervals 
for six hours. Three independent bacterial cultures were assayed for each Y. pestis strain 
in each experiment, and experiments were performed at least twice with neutrophils from 
different donors. 
Platelet aggregation experiments. Whole blood was collected from healthy adult human 
volunteers in compliance with protocols reviewed and approved by the University of 
Massachusetts Medical School Institutional Review Board (IRB). Washed platelets (and 
platelet-free neutrophils, where needed) were isolated as described (92). Platelets were 
diluted to a final concentration of 2x108/mL in HEPES buffer (140 mM NaCl, 6.1 mM 
KCl, 2.4 mM MgSO4.7H20, 1.7 mM Na2HPO4, 5.8 mM Sodium HEPES, 0.35% BSA, 
and 0.1% Dextrose) in the presence of 3 μM purified human fibrinogen, 1 mM CaCl2, 
and 2mM MgCl2. Where specified, luminescent Y. pestis (2x108/mL), neutrophils 
(5x106/mL) and/or 2 μM purified human plasminogen were also included in the reaction. 
(Final ratio of bacteria to platelets to PMNs was 40:40:1.) Aggregation was induced with 
the addition of 0.1 U/mL purified human thrombin (factor IIa), added 1 minute after 
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components were mixed together unless otherwise specified. Platelet aggregation was 
monitored stirring at 37°C in a PAP-4 aggregometer as described (92). 
Localization of luminescent Y. pestis under these same experimental conditions 
was monitored with a Cascade 1K (Photometrics) EM-CCD camera in a custom-built 
apparatus. Luminescence intensity was analyzed with ImageJ. Intensity was measured in 
each frame for three regions: an “upper” region (a rectangle located in the upper half of 
the tube), a “lower” region (a polygon capturing the area immediately surrounding the stir 
bar), and the stir bar region itself. Signal intensity of the stir bar region was multiplied by 
two as an approximate correction for the opacity of the stir bar, and this intensity was 
then added to that measured for the other two regions of interest. This “total” 
luminescence metric in each frame was normalized to the luminescence measured in the 
first frame of the experiment to calculate change in luminescence over time. 
Microscopy of platelet thrombi. Thrombi formed as described above containing Y. 
pestis strains, platelets, fibrinogen, and neutrophils were fixed 13 minutes after the 
addition of thrombin. For confocal microscopy, samples were fixed with IC Fixative 
buffer (Ebioscience cat. #00-8222-49) added 1:1, according to manufacturer’s 
instructions, and then stained with α-CD41a FITC (platelet marker) (Ebioscience cat. 
#11-0419-42), α-CD66b APC (neutrophil marker) (Ebioscience cat. #17-0666-42), and 
DAPI (DNA), and imaged on a spinning disk confocal Nikon TE2000E2 inverted 
microscope. Images were collected on a Photometrics Coolsnap HQ2 camera. Scanning 
electron microscopy was performed as described (92).  
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APPENDIX S2: Reversion of methicillin-suscpetible Staphylococcus aureus to 
methicillin-resistant Staphylococcus aureus during treatment of bacteremia 
 
Preface 
This appendix was published in 2016 as an eponymous manuscript in The Journal of 
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4Department of Medicine/Infectious Disease, Boston University, Boston, Massachusetts 
02215, USA; 
 5Massachusetts Department of Public Health, Jamaica Plain, Massachusetts 02130, USA 
*These authors contributed equally to this report.  
 
As the second author of this manuscript, I independently designed and implemented the 
mathematical analysis of fluctuation test data presented in Figures S2.4, S2.5, and 
Supplementary Note 1. I was involved in manuscript preparation, data analysis, and 
experimental design, including proposing the slipped-strand mispairing model for the 
J522BDU strain shown in Figure S2.6. 
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Introduction 
Resistance of methicillin-resistant Staphylococcus aureus (MRSA) to β-lactam 
antibiotics depends on the production of Penicillin Binding Protein 2a (PBP2a), an 
alternative cell-wall transpeptidase. PBP2a, which binds β-lactams very poorly, replaces 
the transpeptidase function of the native β-lactam-susceptible enzyme PBP2, and is 
encoded by the gene mecA. mecA was acquired by S. aureus from non-pathogenic 
staphylococcal species (250, 251) and current MRSA strains are thought to be derived 
from a small number of original acquisition events (252, 253). When MRSA is isolated 
from patients who were originally diagnosed with methicillin-susceptible Staphylococcus 
aureus (MSSA), it is generally assumed that the original infection was either 
polymicrobial, with MSSA predominating, or that the MRSA resulted from a secondary 
infection event. Because acquisition of the mecA gene is very rare, the development of 
resistance in isolates highly susceptible to methicillin-like antibiotics is considered 
unlikely and has not been rigorously documented in a clinical setting. 
Distinguishing MRSA from MSSA is complicated by phenotypic variability in 
methicillin susceptibility known as heteroresistance, which can produce borderline results 
in clinical assays. In an effort to avoid misclassification of MRSA as MSSA due to this 
phenomenon, some clinical laboratories have begun testing S. aureus isolates for the 
presence of mecA by PCR. A small percentage of strains that are highly susceptible to 
methicillin-like antibiotics by conventional phenotypic methods are also PCR-positive for 
mecA (254-268). Because PCR is substantially faster and more accurate in predicting 
oxacillin resistance, Clinical Laboratory Standards Institute (CLSI) guidelines 
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recommend such strains be reported as oxacillin resistant, although the nature of these 
strains is not understood. One potential explanation for this population of mecA+ MSSA 
is that they are mutants in which mecA has been inactivated. Indeed, mecA expression in 
the absence of β-lactams has been shown to adversely affect in-vitro fitness (269, 270), 
suggesting that selection would favor inactivation of mecA in the absence of antibiotics. 
Whether or not such strains should be treated clinically as MRSA would depend on the 
nature of the inactivating mutations, and in particular on their ability to revert and permit 
expression of resistance. Given the superior efficacy and low toxicity of β-lactam 
antibiotics as compared with alternatives such as vancomycin, treating mutants that do 
not revert, or revert at sufficiently low frequencies, as MRSA may deny some patients 
significant therapeutic benefit. 
Here we report the first clearly defined case of reversion of a genetically 
inactivated mecA gene to an active form within a patient during antibiotic therapy. We 
describe the genetic lesion and the mechanism of reversion for this strain, and also for a 
second clinical isolate from a separate patient that reverts at a similar frequency but via a 
different mechanism.  
Methods 
Bacterial strains and culture conditions. Strains and used and generated in this work 
are described in Supplementary Table 1 of (271). Mueller-Hinton II Cation Adjusted 
broth and agar (MHB and MHA, Difco) supplemented with 4% NaCl or Tryptic Soy 
broth and agar (TSB and TSA, Difco) were used for cultivation of all strains with 
incubation at 37°C unless otherwise specified.  
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PCR. Colony PCR (272) was used to amplify mecA for sequence analysis using primers 
mecAUF and mecADR . mecA PCR products were sequenced by Genewiz, Inc. using 
primers mecAUR and mecADF in addition to mecAUF and mecADR (Supplementary 
Table 2 of (271)).  
Western Blots. Log-phase cultures of S. aureus were diluted into broth containing 0 μg 
ml-1, 0.01 μg ml-1, 0.25 μg ml-1, or 12 μg ml-1 oxacillin. After 1 hour at 37°C, 900 μl of an 
OD600 0.5 equivalent were spun down, re-suspended in 300 μl lysis buffer (15 μg ml-1 
DNase, 15 ug ml-1 RNase, 100 μg ml-1 lysostaphin, 50 mM Tris pH 7.4) and incubated at 
37°C for 30 minutes. Laemmli sample buffer was added to the lysates and they were 
boiled for 5 minutes. Lysates were then separated on 10% SDS polyacrylamide gels, 
transferred to nitrocellulose membranes, and probed with monoclonal antibody specific 
for PBP2a (PBP2a Monoclonal Catalog# 10-P08A, Fitzgerald Industries International). 
Following reaction with a secondary antibody conjugated with the fluorescent dye Cy5 
(Goat anti-Mouse IgG (H+L) Secondary Antibody, Cy® 5 conjugate, Molecular Probes), 
bands were visualized by scanning with a 632 nm laser on a Typhoon 9410 (GE 
Healthcare). Imaging for gross detection of PBP2a was done with a photomultiplier tube 
voltage of 600, 200 μm pixel size, and high sensitivity. Imaging for quantification of 
relative amounts of PBP2a was done at a photomultiplier tube voltage of 300, 50 μm 
pixel size, and normal sensitivity.  
Fluctuation Analysis. The contribution of random and induced mutation to reversion 
was assessed using fluctuation analysis as described by Luria and Delbrück (273). 
Overnight cultures of each strain, grown in TSB at 37°C, were diluted to 3.33x103 cells 
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ml-1 and used to inoculate three 24-well plates with 300 μl per well. After incubation in a 
humidified shaking chamber at 37°C for 24 hours, 100 μl of each culture was plated to 
MHA with 4% NaCl and 12 μg ml-1 oxacillin. The optical density at 600 nm (OD600) was 
also measured for each culture. After incubation at 37°C for 48 hours, the number of 
colonies on each plate was counted. Counts among cultures were normalized to the OD600 
of the cultures measured at the time of plating. 
We developed a custom software tool in C that calculates the number of pre-
plating and post-plating mutation events using a maximum likelihood model.  This 
program fit the OD600-normalized counts to three distributions: (1) the Luria-Delbrück 
distribution, which allows only for random mutation (274, 275), (2) a Gaussian binomial 
approximation, which allows only for induced mutation, and (3) joint distribution model 
in which an additional fitted parameter representing the mean number of induced 
mutations per plate is added to the Luria-Delbrück distribution (276, 277). Although 
induced mutation models are traditionally described by the Poisson distribution, we found 
that this model suffered from overdispersion as a result of plating error. To address this 
problem, we defined the induced mutation parameter as the mean of a Gaussian binomial 
approximation with a fixed standard deviation (mean/4.72) determined by independent 
measurement of variation inherent in the plating process. The best fit was determined by 
Akaike’s Information Criterion (AIC). 
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Results 
 
Figure S2.1. Case timeline. The main time scale bar at the bottom is in weeks, with the two 
hospital admission insets in days. Boxes below the time scale bar indicate type of antibiotic 
therapy, duration, and route of administration. Boxes above the time scale bar indicate times and 
sites of sample acquisition and the organisms recovered. The double box identifies the sample 
yielding MRSA. 
Case Description. A 76 year-old male who had undergone a left total knee arthroplasty 5 
years previously presented with sudden onset of pain and swelling in that knee. 
Aspiration of synovial fluid showed 34,000 white blood cells with 84% 
polymorphonuclear leukocytes. The patient was admitted and treatment begun with 
intravenous vancomycin 1 gram every 12 hours and intravenous levofloxacin 750 
milligrams every 24 hours. Blood and synovial fluid cultures grew S. aureus. 
Susceptibility testing by Vitek AST-GP67 CARD indicated oxacillin susceptible and a 
cefoxitin screen test was negative, thus the isolate was classified as MSSA. Therapy was 
narrowed to vancomycin because of a reported allergy to penicillin. Five days after 
admission, the joint prosthesis was replaced with a tobramycin-impregnated spacer. 
Intraoperative cultures and repeat blood cultures on hospital days 3, 4, and 5 again 
identified MSSA. Neither trans-thoracic nor trans-esophageal echocardiogram found 
evidence of endocarditis. On hospital day 7 therapy was changed to intravenous 
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daptomycin 700 milligrams every 24 hours, but blood cultures on day 10 remained 
positive for MSSA. CT imaging of the chest, abdomen and pelvis revealed only left lower 
lobe pneumonia. Blood cultures on hospital day 12 identified MSSA and antibiotic 
therapy was changed to intravenous linezolid 600 milligrams every 12 hours. On hospital 
day 13, desensitization to nafcillin was performed followed by treatment with intravenous 
nafcillin 2 grams every 4 hours. Blood cultures on hospital day 14 were negative. The 
patient developed lower back pain and an MRI of the lumbar spine showed evidence of 
vertebral osteomyelitis at level of T12-L1 vertebrae. The patient was continued on 
intravenous nafcillin and completed 10 weeks of total antibiotic therapy, remaining 
afebrile and with resolution of back pain. Because of immobility, a urinary catheter was 
maintained, and a screening urine culture grew Klebsiella pneumoniae. 
One week after discontinuing nafcillin, repeat blood cultures were negative. A 
week later, the patient developed fever and sudden onset of severe back pain. Admission 
blood cultures were sterile, but urine culture grew Klebsiella pneumoniae. Intravenous 
vancomycin therapy was reinstituted. On hospital day 6 a biopsy of the T12-L1 disc 
interspace showed Gram-positive cocci in clusters, and culture grew S. aureus resistant to 
oxacillin. The patient was treated with a regimen of intravenous vancomycin, intravenous 
nafcillin, and oral rifampin for 10 weeks. His back pain resolved and inflammatory 
markers normalized. He has had no evidence of recurrence of osteomyelitis in the 
subsequent 4.5 years. A timeline summarizing the significant clinical events is presented 
in Figure S2.1.  
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Reversion to MRSA by precise excision of a transposable element. Microdilution trays for 
full range MIC testing, performed according to CLSI standards, yielded an oxacillin MIC 
of <0.25 µg ml-1 for the blood isolate from first admission (B1) and >32 µg ml-1 for the 
vertebral disc space isolate from readmission (DS1). A MRSA CHROMagarTM screening 
plate also confirmed susceptibility of B1. The MSSA isolate B1 and the MRSA isolate 
DS1 appeared indistinguishable by pulsed-field gel electrophoresis (PFGE), and 
comparison with the fingerprint database maintained by the Massachusetts Department of 
Public Heath revealed an 83% similarity with clonal group USA100 (Supplementary Fig. 
1 of (271)). Multiplex PCR demonstrated that all isolates contained the expected markers 
for S. aureus, contained the mecA gene, were distinguishable from the common MRSA 
USA300 clonal group, and were negative for Panton-Valentine leukocidin (PVL) 
(Supplementary Fig. 2 of (271)).  
As the above results indicated that the MRSA and MSSA isolates were clonal, we 
next asked whether the MSSA isolate could give rise to resistant clones. Three 
independent MSSA isolates from the patient (B1, B2, and SF1) were streaked heavily on 
MHA containing 4% NaCl and 6 µg ml-1 oxacillin. In all cases, numerous colonies grew 
in the heavy zone of the streak pattern. These colonies grew well when re-streaked on the 
same medium (Figure S2.2A). MICs of these resistant revertants were >64 µg ml-1. 
The original MSSA isolates were positive for mecA in multiplex PCR with primers 
producing a short product (147 bp). To determine if the full-length mecA gene was 
present, PCR primers homologous to the 5’ and 3’ ends of mecA were used to amplify the 
mecA coding region. This yielded a product of the expected size (2 kb) in all resistant 
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revertants but a 3.5 kb product in all MSSA parents (Figure S2.2B). Sequencing revealed 
that mecA in the MSSA isolates was interrupted by insertion of the transposable element 
IS1181 after codon 545 of 669, and that the revertants had precisely excised this 
transposable element from mecA (Figure S2.2C). Western blots confirmed that this 
insertion prevents expression of full-length PBP2a (Figure S2.3). 
 
Figure S2.2. B1 reverts to MRSA by precise excision of a transposable element. (a) Streak 
patterns of B1 on non-selective MHA (left) and MHA containing 6 μg ml-1 oxacillin (center). 
Two colonies from the center plate are restreaked on oxacillin (right). (b) Full length mecA PCR 
illustrating the 1.5 kb size difference between susceptible and resistant isolates. Lanes 1-3: 
replicate colonies from strain B1. Lanes 4-7: resistant revertants of B1 obtained from selection on 
oxacillin as in (a). Lane 8: isolate DS1. Similar results were obtained with B2 and SF1. (c) 
Structure of mecA::IS1181 determined by sequencing. Pointed ends of genes indicate direction of 
transcription. All DNA added by the insertion is shaded. The IS1181 transposase is flanked by 23 
base-pair imperfect inverted repeats (black hashed rectangles) which facilitate transposase 
binding and insertion at a target sequence. An 8 base pair duplication of the transposase target 
sequence in the mecA gene (ATATTAAC) is created when IS1181 inserts. One copy of this direct 
repeat is removed when the transposable element undergoes precise excision, restoring the wild-
type mecA sequence. See Supplementary Figure 3 of (271) for additional details.   
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Figure S2.3. Revertants express PBP2a in an 
oxacillin inducible manner. Western blots with 
PBP2a-specific monoclonal antibody were used to 
examine the products of mecA in the susceptible 
strain B1, the resistant revertant B1R, and the 
vertebral disk space MRSA isolate DS1. Because the 
cassette containing the mecA gene was determined to 
be an SCCmec type II variant (Supplementary Fig. 4 
of (271)) and expression of mecA in SCCmec type II 
cassettes is often induced by β-lactams, we treated 
cultures with the specified concentrations of oxacillin 
for one hour. Lane 1. Extract from B1 exposed to 
0.25 μg ml-1 oxacillin for 1 hour shows a faint band 
of the size predicted by the mecA::IS1181 sequence 
(solid circles •) (63 kDa; Fig. 1C) and several degradation products (open circles ○). No 
detectable PBP2a is produced by the B1 strain in the absence of induction by oxacillin 
(Supplementary Fig. 5 of (271)). Lane 2 and 3. Full-length PBP2a produced by the B1R resistant 
revertant and DS1 isolate treated similarly.  
 
We noticed that the frequency of revertants among independent cultures of B1 
was remarkably constant, leading us to suspect that reversion was induced by exposure to 
oxacillin. To test this hypothesis, we performed fluctuation analysis using 72 independent 
cultures of B1 to calculate the frequency of reversion to oxacillin resistance. The 
fluctuation test, first described by Luria and Delbrück (273), distinguishes between 
random and induced mutation. Cultures grown in non-selective liquid medium are plated 
on selective agar, and resistant colonies are counted. Resistant mutants that arise early 
during growth in a non-selective liquid culture will have many descendants, and will 
therefore produce many colonies, while those that occur late will have fewer. Under these 
circumstances of random mutation in non-selective culture, the number of resistant 
colonies obtained follows the Luria-Delbrück distribution, which has a large standard 
deviation. However, if mutations occur primarily on the plate during exposure to the 
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antibiotic, seeding replicate plates with a given number of bacteria should yield similar 
numbers of resistant colonies. Therefore, post-plating mutation events result in a smaller 
standard deviation than that predicted by the Luria-Delbrück distribution (273, 278). 
Induction of IS1181 excision by oxacillin in the plating medium would have this effect. 
Surprisingly, we found that 92% of reversion events occur after exposure to oxacillin, 
indicating that oxacillin significantly increases the rate of precise excision of IS1181 
from mecA (Figure S2.4A). The frequency of reversion was 4x10-7. In comparison, when 
fluctuation analysis was performed for mutation to rifampicin resistance for the hyper-
mutable E. coli ∆mutS, mutation was found to be entirely random, as expected (Figure 
S2.4B). See also Supplementary Note 1, reproduced from (271) at the end of this chapter 
(page 145).  
Because antibiotic-mediated induction of precise excision has not been previously 
reported, we investigated the mechanism of induction. Although read-through 
transcription of the IS1181 transposase from the mecA promoter is induced by oxacillin 
(Supplementary Fig. 6 of (271)), deletion of the transposase from mecA::IS1181 had no 
effect on induced precise excision (Figure S2.4B). Consistent with this observation, 
virtually all studies of precise excision of classical transposable elements like IS1181 
have shown this process to be independent of transposase activity (279-281). Previous 
reports have shown that precise excision depends on intra-strand hybridization of the 
inverted repeats, followed by slipped-strand mispairing during replication between the 
direct repeats formed by target site duplication, or by resolution of the resulting cruciform 
structure via a pathway dependent on the exonuclease SbcD (282). SbcD is up-regulated 
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during the SOS response, which is induced by some antibiotics, including β-lactams 
(283-286). However, neither inactivation of SOS nor deletion of sbcD affected the 
induced reversion rate to oxacillin resistance (Figure S2.4B), indicating that oxacillin 
induces precise excision of IS1181 from mecA via an SOS-independent and SbcD-
independent mechanism. In contrast, rifampicin-induced SOS responses in B1 increased 
mutation to rifampicin resistance, which requires a point mutation resulting in an amino 
acid substitution in rpoB.  
 
Figure S2.4. Reversion to resistance is induced by oxacillin. (a) Cumulative distribution of 
colony counts obtained by plating 72 independent cultures of B1 on MHA plates containing 12 
μg ml-1 oxacillin (solid circles •). The dashed line shows the MSS maximum likelihood fit of the 
Luria-Delbrück distribution to these counts, which allows only for random mutation and fits the 
data poorly. To account for mutations occurring during selection on plates, we fitted a joint 
distribution model in which the additional parameter represents the mean number of induced 
mutations per plate (276, 277). The solid line shows the maximum likelihood fit of the joint 
model. (b) Left: The best fit (as determined by Akaike’s Information Criterion) of the data for B1 
estimates 2 of 30 reversion events (8%) occur pre-plating (random) and 28 of 30 of reversion 
events (92%) occur post-plating in the presence of selection (induced). Mutations in a variety of 
genes related to precise excision, mecA transcription, and SOS had no effect on induced reversion 
to oxacillin resistance. Right: Unlike reversion to oxacillin resistance, mutation to rifampicin 
resistance in the B1 isolate is a primarily random process. Post-plating mutation to rifampicin 
resistance is mediated by the SOS response, as shown by the decrease in induced mutation events 
when SOS is constitutively repressed by the expression of non-cleavable LexAG94E (277). In the 
hypermutable E. coliΔmutS strain, all mutations to rifampicin resistance occur randomly. 
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Because transcription increases supercoiling and enhances cruciform formation 
(287), increased transcription over IS1181 during oxacillin exposure could promote 
precise excision and increase reversion rates. However, in a derivative of B1 
constitutively transcribing mecA due to deletion of the regulatory genes mecI/mecRI and 
blaI/blaRI (Supplementary Fig. 6 of (271)), precise excision remained induced.  
Taken together, these results have led us to reject the a priori hypotheses that appear 
most likely to explain the induction of precise excision. The mechanism underlying this 
phenomenon remains to be determined. 
Reversion to MRSA by correction of a frame-shift mutation. Our experience with strain 
B1 lead us to examine the properties of another clinical isolate that, like B1, was highly 
susceptible to oxacillin by broth microdilution (MIC 0.5 µg ml-1), but was mecA positive 
by PCR (Xpert MRSA/SA SSTI; Cepheid). The patient had a history of S. aureus 
infections associated with abscesses and line insertion sites and was treated at several 
hospitals, so tracing a definitive clinical history is difficult. At the time the MSSA isolate 
was collected, the patient was treated with vancomycin. Blood cultures in the following 
month were negative. 
The ability of this strain, J522BDU, to give rise to resistant clones was first 
assessed by streaking heavily on MHA containing 4% NaCl and 12 µg ml-1 oxacillin. 
Like B1, numerous colonies grew in the heavy zone of the streak pattern. These colonies 
grew well when re-streaked on the same medium. MICs of these resistant revertants were 
>64 µg ml-1. A small amount of full-length PBP2a was present in J522BDU cultures, but 
the resistant revertant J522BDU-R produced eight-fold more (Figure S2.5A). 
 138 
Fluctuation analysis of J522BDU yielded a reversion frequency of 9x10-8, about 4-fold 
lower than that of B1. Unlike B1, reversion of J522BDU seems to be a random process 
that is not induced by oxacillin (Figure S2.5B). 
 
Figure S2.5. Reversion in J522BDU occurs randomly and increases expression of PBP2a. (a) 
Western blots with PBP2a-specific monoclonal antibody were used to examine the products of 
mecA in oxacillin-susceptible J522BDU and in J522BDU-R, a resistant revertant derived from 
J522BDU by streaking on MHA 4% NaCl containing 0.25 μg ml-1 oxacillin. Because the cassette 
containing the mecA gene was determined to be an SCCmec type II (Supplementary Fig. 4 of 
(271)), we treated cultures with the specified concentrations of oxacillin for one hour prior to 
preparation for electrophoresis as in Figure 3. Lane 1. Extract from J522BDU exposed to 0.25 μg 
ml-1 oxacillin for 1 hour shows a faint band the size of full-length PBP2a. Lane 2. Full-length 
PBP2a produced by the J522BDU-R resistant revertant treated similarly. The revertant J522BDU-
R produces 8-fold more PBP2a as compared to the susceptible parent J522BDU. (b) Fluctuation 
analysis performed as described for B1 estimates 4 of 14 reversion events (26%) occur pre-
plating (random) and 10 of 14 reversion events (74%) occur post-plating in the presence of 
selection. This is similar to the pattern observed for B1 reversion to rifampicin, indicating that 
SOS responses post-plating are likely responsible for these post-plating reversion events. 
 
To determine the mechanism of reversion, we sequenced the mecA coding region 
for the susceptible isolate J522BDU and nine independent revertants selected by growth 
on MHA 4% NaCl with 12 µg ml-1 oxacillin. As seen in Figure S2.6A, J522BDU has a 
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single nucleotide deletion early in the coding region of mecA resulting in an altered 
reading frame and premature termination at an early stop codon. The small amount of 
PBP2a protein still produced by this strain (seen in Figure S2.5A) most likely results 
from misreading at the ribosome level, which is known to occur in stretches of repeated 
nucleotides. 
We analyzed nine independent revertants that all correct this frame-shift mutation 
by inserting an additional nucleotide at or near the site of the deletion. Of these, six 
corrected the frame-shift by extending the neighboring stretch of repeated nucleotides 
just downstream of the deletion (Sequence I, Figure S2.6A). The other three revertants all 
corrected the frame-shift by inserting a nucleotide in different positions nearby (Sequence 
II, III, and IV, Figure S2.6A). All revertants restored the reading frame of mecA (Figure 
S2.6B). Because this stretch of repeated nucleotides is highly conserved in mecA genes, 
the insertion and deletion of single bases by slipped-strand mispairing could be a fairly 
common phenomenon to modulate PBP2a production in mecA-positive S. aureus.  
 
Figure S2.6 (next page). J522BDU reverts to oxacillin resistance by slipped-strand 
mispairing. Gray shaded sequence indicates consensus with wild-type mecA and PBP2a. 
Nucleotides inserted during reversion are in bold. (a) Sequencing of oxacillin susceptible 
J522BDU revealed a single ‘A’ deletion from a stretch of 7-‘A’s at positions 255-261. This 
results in a frame-shift and an early stop codon at positions 283-285 (boxed). Of the nine 
independent revertants sequenced, six revert to Sequence I and one each was observed for 
Sequence II, III and IV. The frame-shift and correcting insertions occur in the N-terminal 
extension of PBP2a, a region that has no enzymatic activity and unknown function (288). (b) All 
revertants eliminated the early stop codon at residue 95 by correcting the reading frame. 
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Discussion 
Our clinical experience with the patient described above and our analysis of 
additional mecA+ MSSA strains that revert to MRSA provide a framework for 
considering the implications of such strains for treatment strategies, antibiotic 
susceptibility testing, and reporting of resistance profiles. These strains have three 
properties that distinguish them as a class: frank sensitivity to oxacillin when assessed by 
the standard CLSI phenotypic methods used in clinical microbiology laboratories, 
presence of a mecA gene which is detectable by PCR but is genetically inactivated, and 
the generation of resistant revertants at modest frequencies (~10-7). This reversion 
frequency falls within a troublesome window: it is low enough to escape detection by 
standard phenotypic methods because the bacterial inocula used in these assays are small 
(105 CFU), but high enough to allow significant risk for development of resistance 
leading to treatment failure under monotherapy.  
We observed two distinct mechanisms of reversion in strains with inactivated 
mecA: (1) precise excision of the transposable element IS1181 from within mecA and (2) 
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slip-strand replication errors within mecA. Although the precise excision of IS1181 is a 
remarkable example of induced mutation and gives rise to revertants at a higher rate, the 
slipped-strand mechanism is more concerning as it arises from sequence properties 
common to all mecA genes. In bacteria, cycles of positive and negative selection acting 
on expression of a particular gene often give rise to genetic systems that ensure 
populations include some individuals in the currently disadvantaged state of expression, 
although these may be rare. In its simplest incarnation, this phenomenon, known as phase 
variation, is mediated by slipped-strand mutagenesis in low entropy sequences 
characterized by stretches of repeated nucleotides (e.g. (289)). This is essentially what we 
observe in strain J522BDU as it converts from mecA+ MSSA to MRSA.  
Although the case we describe here is the first rigorously documented instance in 
which a methicillin-susceptible strain reverted to high-level β-lactam resistance during 
antibiotic therapy, other reports suggest similar events have occurred (257, 260). Our 
analysis of the extant literature (254-265, 267, 268) estimates the frequency of mecA+ 
MSSA at approximately 3% of clinical S. aureus isolates (see Supplementary Table 3 of 
(271)), suggesting that such strains cause a large number of clinically significant 
infections annually in the United States (290, 291), which may currently be misidentified 
as MSSA/MRSA polymicrobial infections. The fitness cost associated with the presence 
of a functional mecA gene (269, 270) provides a selection pressure for mecA inactivation 
in the absence of antibiotic, predicting the presence of a population of mecA+ MSSA. 
There is very little information regarding the fraction of mecA+ MSSA that are capable of 
reversion to MRSA. In vitro reversion has been observed previously, (255, 259, 260, 262-
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264, 292) but the genetic mechanisms have not been investigated. The rates of reversion 
we observe are of the same order of magnitude as spontaneous resistance to rifampicin, 
which is often prescribed as part of combination therapy to prevent the emergence of 
resistant mutants.  
Reporting mecA+ MSSA as MRSA is likely to restrict treatment to β-lactam 
alternatives such as trimethoprim-sulfamethoxazole, doxycycline, or vancomycin, which 
are considered inferior (293, 294). Laboratory methods that combine both genotypic and 
phenotypic testing to distinguish among MRSA, MSSA, and mecA+ MSSA would 
provide clinicians with a more complete characterization of infecting strains. In the latter 
case, this would encourage the potentially more efficacious therapeutic strategy of 
including a β-lactam in combination with a second agent to control any small revertant 
population that may arise during therapy. 
In addition to clinical implications, the existence of mecA+ MSSA strains capable 
of reversion to MRSA also has regulatory and legal ramifications. Multiple U.S. states, 
the Veterans Affairs Healthcare system, and several nations have mandated screening and 
isolation programs for MRSA  although the efficacy of these programs is unclear (295-
297). If mecA+ MSSA isolates ultimately fall under the legal definition of MRSA, truly 
comprehensive screening programs will need to incorporate genotypic testing, as 
phenotypic testing alone is insufficient to identify mecA+ MSSA. 
Our findings illustrate a generic principle inherent in the use of strictly genotypic 
information to predict resistance phenotypes: the presence of a gene does not guarantee 
that it is expressed, and withholding highly effective antibiotics based solely on 
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genotypic information may be harmful, especially when alternatives are limited. This 
potential for harm warrants explicit and careful consideration during development and 
implementation of molecular diagnostics. 
Funding 
This work was supported by unrestricted research funds from the University of 
Massachusetts Medical School [J.D.G.]; the National Institutes of Health [T32 AI095213 
to S.G.P.]; and the National Institute of Allergy and Infectious Diseases/ National 
Institutes of Health [HHSN272200700055C to S.W.]. 
Acknowledgements 
We would like to acknowledge S. Baker for statistical advice regarding the Poisson 
distribution and overdispersion. We are also grateful to K. Hazen of Duke University for 
sending us strain J522BDU.  
 
  
 144 
Supplementary Note 1: Fluctuation analysis. 
Fluctuation analysis was performed twice independently for each strain of 
interest, with the exception of the three experiments plated on rifampicin, which were 
performed once. The table below gives fluctuation test results for each strain. The m 
parameter represents the number of random mutation events in liquid (non-selective) 
culture, while the mu parameter represents the number of post-plating (induced) mutation 
events. Each dataset was fit to models allowing for random mutation only (Luria-
Delbrück model), induced/post-plating mutation only (Gaussian model), or both types of 
mutation events (joint model). Each model was assessed for goodness-of-fit by Akaike’s 
Information Criterion (AIC), which accounts for model complexity by penalizing models 
for including additional parameters. Lower AIC values represent a better fit (shaded 
parameters).  
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Discussion of fluctuation analysis results. Fluctuation analysis of B1 indicated 92% of 
reversion events occurred as the result of induction by oxacillin (27.9 induced versus 2.2 
random; row 1 in above Table). To further understand the mechanism of induced precise 
excision of IS1181 from the mecA gene, we constructed several mutants of B1. Each 
mutant was tested to determine whether it had lost its ability to induce reversion in the 
presence of oxacillin. 
First, we constructed an in-frame deletion of the mecA::IS1181-encoded 
transposase (B1 mecA∆IS1181TPase, row 5 in above Table). This deletion had no effect on 
the incidence of induced mutation. This is not surprising, as virtually all studies of precise 
excision have shown this process to be independent of transposase activity, and that 
endogenous bacterial factors mediate the precise excision process (279-281, 298, 299). 
Exposure to antibiotics can induce bacterial stress responses, which have been 
linked to increased movement of transposable elements both in S. aureus and in other 
pathogens (300-303) (reviewed in (304)). Therefore, we tested the hypothesis that 
induction of these stress responses by β-lactams stimulates host-mediated precise 
excision of IS1181 from the mecA gene. First, we investigated the effect of the SOS 
response on precise excision by constructing B1lexAG94E, a non-cleavable lexA mutant of 
B1 that results in constitutive repression of SOS (284, 305, 306). Although rifampicin-
induced SOS responses in the B1 isolate increase mutation to rifampicin resistance (rows 
2 and 3 in above Table), the B1lexAG94E strain was not impaired in inducing mutation to 
resistance in the presence of oxacillin (row 6 in above Table). This indicates that SOS 
responses are not responsible for the increased precise excision of IS1181 in the presence 
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of β-lactams. We also constructed a B1 recA null mutant to test the dependence of 
induced mutation on the SOS response and recombination-based DNA repair systems. 
Consistent with the results of the B1lexAG94E mutant, the B1ΔrecA mutant had no defect 
in induced mutation (row 7 in above Table).   
 Because the mechanism of reversion involves the precise excision of IS1181, we 
next investigated whether induced mutation is dependent on the endogenous exonuclease 
SbcD, which is involved in precise excision of cruciforms (282), and is up-regulated 
during the SOS response. We created an in-frame deletion of sbcD in B1, however no 
change in induced mutation was observed (row 8 in above Table). 
Transcription of mecA is induced by β-lactams. The mecA gene is tightly 
regulated by the repressor/inducer pair mecR1/mecI that initiates transcription of the gene 
only in the presence of oxacillin and related drugs (307-309). The β-lactamase 
repressor/inducer pair blaR1/blaI also regulate mecA in S. aureus strains that carry the 
penicillinase plasmid (310, 311), including strain B1. Because transcription increases 
supercoiling and enhances cruciform formation (287), increased transcriptional activity 
over IS1181 could promote precise excision and increase reversion rates in the presence 
of oxacillin. We created a mutant strain of B1 with in-frame deletions of mecRI, mecI, 
and curing the penicillinase plasmid (pPCase) via passage at high temperature (see 
Supplementary Methods). These mutations result in constitutive expression of mecA (see 
Supplementary Fig. 6). Induced mutation in this strain, called B1 mecAconstitutive, was not 
changed (row 10 in above Table). 
 147 
Controls for post-plating survival during fluctuation analysis. Strictly speaking, the 
fluctuation test measures the number of mutation events that occur pre-plating (in liquid 
culture) and those that occur post-plating (during antibiotic exposure on the plate). 
However, growth or prolonged survival of susceptible bacteria in the presence of 
antibiotic may provide a limited window during antibiotic exposure that permits survival, 
mutation, and the development of true resistance. This would skew fluctuation test results 
towards post-plating mutation, even if mutation rates were not induced in the presence of 
the antibiotic. 
We confirmed that stationary phase cells of strain B1 exposed to 12 μg ml-1 
oxacillin were unable to complete a single generation of growth, indicating that the 
higher number of mutations occurring on the plate is not due to post-plating population 
expansion (see below). 
  
Survival in the absence of population expansion, or tolerance, could also 
complicate fluctuation test analysis, as it provides more time for bacteria to accumulate 
random mutations. Inactivating mutations in the gene gdpP (also known as yybT in B. 
subtilis) has been found to confer β-lactam tolerance in S. aureus, although the function 
of gdpP is poorly understood (312). To assess tolerance of B1, we performed tolerance 
assays (see Supplementary Methods of (271)) to compare B1, RN4220 (a susceptible 
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laboratory S. aureus strain), and a null mutant of gdpP in RN4220. As expected, 
RN4220ΔgdpP was tolerant to oxacillin, while RN4220 was killed by the drug. Like 
RN4220, B1 failed to meet the criteria for tolerance to oxacillin in this assay 
(Supplementary Figure 7). Therefore, the observed post-plating mutations of B1 in the 
fluctuation tests above are likely a result of induced mutation, rather than continuing 
random mutation processes in live bacteria post-plating. 
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